<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">56309</article-id><article-id pub-id-type="doi">10.7554/eLife.56309</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>BAD inactivation exacerbates rheumatoid arthritis pathology by promoting survival of sublining macrophages</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-177315"><name><surname>Li</surname><given-names>Jie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5446-894X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-177316"><name><surname>Zhang</surname><given-names>Liansheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6444-6421</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177317"><name><surname>Zheng</surname><given-names>Yongwei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177318"><name><surname>Shao</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177319"><name><surname>Liang</surname><given-names>Qianqian</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177320"><name><surname>Yu</surname><given-names>Weida</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-8346"><name><surname>Wang</surname><given-names>Hongyan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99881"><name><surname>Zou</surname><given-names>Weiguo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2516-0302</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177321"><name><surname>Wang</surname><given-names>Demin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177322"><name><surname>Xiang</surname><given-names>Jialing</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-176374"><name><surname>Lin</surname><given-names>Anning</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2754-5134</contrib-id><email>anninglin@nju.edu.cn</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>The State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>School of Life Science and Technology, ShanghaiTech University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Ben May Department for Cancer Research, The University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Institute of Modern Biology, Nanjing University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Blood Research Institute, Blood Center of Wisconsin</institution><addr-line><named-content content-type="city">Milwaukee</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Orthopaedics, Longhua Hospital, Shanghai University of Traditional Chinese Medicine</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution>Department of Biology, Illinois Institute of Technology</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution>Indian Institute of Science Education and Research (IISER)</institution><country>India</country></aff></contrib><contrib contrib-type="editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Reviewing Editor</role><aff><institution>Yale School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>03</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e56309</elocation-id><history><date date-type="received" iso-8601-date="2020-02-24"><day>24</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-17"><day>17</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Li et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-56309-v1.pdf"/><abstract><p>The resistance of synovial sublining macrophages to apoptosis has a crucial role in joint inflammation and destruction in rheumatoid arthritis (RA). However, the underlying mechanism is incompletely understood. Here we report that inactivation of the pro-apoptotic BCL-2 family protein BAD is essential for survival of synovial sublining macrophage in RA. Genetic disruption of <italic>Bad</italic> leads to more severe joint inflammation and cartilage and bone damage with reduced apoptosis of synovial sublining macrophages in collagen-induced arthritis (CIA) and TNFα transgenic (TNF-Tg) mouse models. Conversely, <italic>Bad<sup>3SA/3SA</sup></italic> mice, in which BAD can no longer be inactivated by phosphorylation, are protected from collagen-induced arthritis. Mechanistically, phosphorylation-mediated inactivation of BAD specifically protects synovial sublining macrophages from apoptosis in highly inflammatory environment of arthritic joints in CIA and TNF-Tg mice, and in patients with RA, thereby contributing to RA pathology. Our findings put forward a model in which inactivation of BAD confers the apoptosis resistance on synovial sublining macrophages, thereby contributing to the development of arthritis, suggesting that BAD may be a potential therapeutic target for RA.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>BAD</kwd><kwd>macrophages</kwd><kwd>rheumatoid arthritis</kwd><kwd>apoptosis</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM103868</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Anning</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA195526</award-id><principal-award-recipient><name><surname>Xiang</surname><given-names>Jialing</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI079087</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Demin</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL130724</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Demin</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31430026</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Anning</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>91329301</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Anning</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Phosphorylation-mediated inactivation of pro-apoptotic BCL-2 family protein BAD confers the apoptosis resistance on synovial sublining macrophages, thereby contributing to the development of rheumatoid arthritis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that primarily affects diarthrodial joints, characterized by hyperplasia of intimal lining, infiltration of macrophages, and lymphocytes in synovial sublining and joint destruction (<xref ref-type="bibr" rid="bib14">Firestein, 2003</xref>; <xref ref-type="bibr" rid="bib35">McInnes and Schett, 2011</xref>). Macrophage is one of the most abundant cell types in RA synovium and different subgroups of synovial macrophages play distinct roles in the development of RA (<xref ref-type="bibr" rid="bib58">Udalova et al., 2016</xref>). Locally self-renewing tissue-resident macrophages, which mainly locate in synovial lining layer, have anti-inflammatory function and maintain tissue homeostasis for intra-articular structures (<xref ref-type="bibr" rid="bib1">Ambarus et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Culemann et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Uderhardt et al., 2019</xref>). By contrast, the infiltrating macrophages derived from monocytes, which largely locate in synovial sublining layer in inflamed synovium, are the major source of joint inflammation and cause cartilage and bone destruction by secreting pro-inflammatory cytokines including TNFα, IL-1β and IL-6, and matrix metalloproteinases (MMPs) (<xref ref-type="bibr" rid="bib24">Kennedy et al., 2011</xref>; <xref ref-type="bibr" rid="bib48">Siouti and Andreakos, 2019</xref>). Reduced number of synovial sublining macrophages correlates with clinical improvement in RA patients (<xref ref-type="bibr" rid="bib4">Bresnihan et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Haringman et al., 2005</xref>) and elimination of macrophages by clodronate-containing liposomes prevents arthritis development in murine models and patients with RA (<xref ref-type="bibr" rid="bib3">Barrera et al., 2000</xref>; <xref ref-type="bibr" rid="bib42">Richards et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Solomon et al., 2005</xref>), indicating a critical role of the synovial sublining macrophages in promoting RA progression.</p><p>Defective apoptosis contributes to the survival and accumulation of synovial sublining macrophages (<xref ref-type="bibr" rid="bib27">Li et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Pope, 2002</xref>), which is an early RA hallmark that correlates with joint inflammation and bone destruction (<xref ref-type="bibr" rid="bib53">Tak et al., 1997</xref>; <xref ref-type="bibr" rid="bib58">Udalova et al., 2016</xref>). In inflamed joint, persistent activation of a variety of signaling pathways in macrophages, such as NF-κB signaling pathway and PI3K-Akt signaling pathway (<xref ref-type="bibr" rid="bib17">Handel et al., 1995</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2001</xref>; <xref ref-type="bibr" rid="bib61">Vergadi et al., 2017</xref>), protects macrophages from cell death under inflammatory condition in RA synovium. In addition, upregulated expressions of several anti-apoptotic proteins such as myeloid cell leukemia 1 (MCL-1) (<xref ref-type="bibr" rid="bib31">Liu et al., 2006</xref>), cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) (<xref ref-type="bibr" rid="bib19">Huang et al., 2017</xref>), transcription factor nuclear factor of activated T cells 5 (NFAT5) (<xref ref-type="bibr" rid="bib6">Choi et al., 2017</xref>), and microRNA such as <italic>Mir-155</italic> (<xref ref-type="bibr" rid="bib26">Kurowska-Stolarska et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Rajasekhar et al., 2017</xref>) have also been reported to promote synovial macrophage survival via inhibiting apoptosis in RA. However, direct genetic evidence that is responsible for the apoptosis resistance of synovial sublining macrophages is still lacking. Although genetic disruption of pro-apoptotic protein BID or BIM aggravates arthritis in K/BxN mouse model (<xref ref-type="bibr" rid="bib44">Scatizzi et al., 2006</xref>; <xref ref-type="bibr" rid="bib45">Scatizzi et al., 2007</xref>) and BH3 domain mimetic peptide treatment has also been reported to ameliorate arthritis development (<xref ref-type="bibr" rid="bib46">Scatizzi et al., 2010</xref>), the underlying mechanism and targeting cell type are not known.</p><p>The pro-apoptotic BCL-2 family protein BAD has a critical role in mitochondrial-dependent apoptosis and involves in the development of many diseases by regulating cell death, such as diabetes, tumorigenesis, epilepsy, and sepsis shock (<xref ref-type="bibr" rid="bib10">Danial et al., 2008</xref>; <xref ref-type="bibr" rid="bib16">Foley et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Sastry et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Yan et al., 2018</xref>). The pro-apoptotic activity of BAD is inhibited by survival factors or growth factors such as IL-3 and EGF through activation of a group of protein kinases, such as Rsk2, PKA, Akt/PKB, and JNK1, which phosphorylate BAD at Ser112, Ser136, Ser155, and Thr201, respectively (<xref ref-type="bibr" rid="bib9">Danial, 2008</xref>; <xref ref-type="bibr" rid="bib68">Yu et al., 2004</xref>). Upon withdrawing survival factors or growth factors, dephosphorylated BAD will translocate to mitochondria, where it inactivates pro-survival BCL-2 family proteins BCL-2 and BCL-X<sub>L</sub> to trigger apoptosis (<xref ref-type="bibr" rid="bib67">Yang et al., 1995</xref>). The pro-apoptotic activity of BAD is also inhibited by TNFα through activation of inhibitor of nuclear factor kappa-B kinase (IKK), which phosphorylates BAD at Ser26. The Ser26-phosphorylation primes BAD to be further phosphorylated at Ser112, Ser136, and Ser155 by other protein kinases, thereby preventing BAD from translocation to mitochondria to induce apoptosis (<xref ref-type="bibr" rid="bib65">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="bib66">Yan et al., 2018</xref>). In the chronic inflammatory environment of RA synovium, TNFα-induced IKK activation may inhibit BAD-dependent apoptosis in the sublining macrophage, while increased level of growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are majorly produced by synovial macrophages and involved in angiogenesis, fibrosis, and synovial inflammation (<xref ref-type="bibr" rid="bib52">Szekanecz and Koch, 2007</xref>), may also be responsible for BAD inactivation in macrophage by activating Akt (<xref ref-type="bibr" rid="bib50">Son et al., 2014</xref>), thereby contributing to synovial sublining macrophage survival and RA progression. However, the role of BAD in the development of RA has yet to be studied. Here we report that phosphorylation-mediated inactivation of BAD is increased in synovial sublining macrophage both in arthritic joints of mice and RA patients and <italic>Bad</italic> loss aggravates arthritis in both CIA model and TNFα transgenic (TNF-Tg) mouse model by promoting survival of synovial sublining macrophages. Conversely, constitutive activation of BAD protects mice from collagen-induced arthritis (CIA). Our study demonstrates that inactivation of BAD has a critical role in promoting the progression of RA by regulating synovial sublining macrophage survival.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Bad</italic> loss aggravates CIA</title><p>To investigate the role of BAD in RA, we established CIA model in <italic>Bad</italic><sup>−/−</sup> mice and wild-type (WT) littermates, since the murine CIA model resembles most pathological features of human RA (<xref ref-type="bibr" rid="bib47">Schinnerling et al., 2019</xref>). The disease incidence was much higher and the arthritis was much severer in <italic>Bad</italic><sup>−/−</sup> mice compared with WT littermates in CIA model (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Histopathological analysis showed significantly increased synovitis, pannus formation, as well as cartilage and bone destruction in <italic>Bad</italic><sup>−/−</sup> mice compared with WT littermates (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). Although there was no detectable difference in bone phenotype between <italic>Bad</italic><sup>−/−</sup> mice and WT littermates at basal level (<xref ref-type="fig" rid="fig1">Figure 1B,D</xref>), X-ray and Micro-CT revealed that bone destruction was severer in <italic>Bad</italic><sup>−/−</sup> mice in CIA (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Consistently, <italic>Bad</italic><sup>−/−</sup> mice had increased number of osteoclasts and higher mRNA expression levels of osteoclast marker <italic>TRAP</italic> and <italic>Ctsk</italic> in the joints compared with WT littermates in CIA model (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). However, when osteoclast differentiation was induced from bone marrow-derived macrophages (BMDMs) isolated from WT and <italic>Bad</italic><sup>−/−</sup> mice in vitro, there was no significant difference in the number or mRNA expression levels of <italic>TRAP</italic> and <italic>Ctsk</italic> between WT and <italic>Bad</italic><sup>−/−</sup> osteoclasts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C,D</xref>). These results suggest that overly activation of osteoclasts in the synovium of <italic>Bad</italic><sup>−/−</sup> mice in CIA model is not likely the result of <italic>Bad</italic> loss-induced direct differentiation of osteoclasts, but most likely due to increased levels of pro-inflammatory cytokines such as TNFα, which is known to promote osteoclastogenesis (<xref ref-type="bibr" rid="bib62">Wei et al., 2005</xref>; <xref ref-type="bibr" rid="bib64">Wu et al., 2017</xref>). In support of this notion, the levels of circulating collagen II-specific IgG and its subtypes in the serum after immunization were significantly elevated in <italic>Bad</italic><sup>−/−</sup> mice, as analyzed by ELISA (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Quantitative PCR (qPCR) revealed that the mRNA levels of pro-inflammatory cytokines such as TNFα, IL-6, IL-1β, and MMPs like MMP-3 and MMP-13 in the joint were significantly increased, while anti-inflammatory cytokine IL-10 was decreased in <italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Consistently, ELISA analysis showed that the protein levels of pro-inflammatory cytokines such as TNFα, IL-6, and IL-1β were also increased in the serum of <italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). These results demonstrate that <italic>Bad</italic><sup>−/−</sup> mice are more susceptible to CIA.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Bad</italic> loss aggravates collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Incidence and clinical scores of wild-type (WT; n = 12) and <italic>Bad</italic><sup>−/−</sup> (n = 12) mice in CIA model. (<bold>B</bold>) H &amp; E and Safranin O staining in ankle joint sections of WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model and untreated control mice, ankle joints were harvested 63 days after primary immunization. Scale bar, 500 μm; magnified inset, 100 μm. (<bold>C</bold>) Evaluation of synovitis, pannus, and erosion of ankle joints of WT (n = 12) and <italic>Bad</italic><sup>−/−</sup> (n = 12) mice in CIA model. (<bold>D</bold>) Representative photographs and radiographs of the hind paws of WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model and untreated control mice. (<bold>E</bold>) Circulating levels of collagen II-specific antibodies in serum of WT (n = 12) and <italic>Bad</italic><sup>−/−</sup> (n = 12) mice in CIA model were determined by ELISA. (<bold>F</bold>) Relative mRNA expression levels of pro-inflammatory cytokines (TNFα, IL-6, and IL-1β), matrix degradation enzymes (MMP-3 and MMP-13), and anti-inflammatory cytokine IL-10 in the joints of WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 9) mice in CIA model were determined by real-time qPCR. (<bold>G</bold>) Protein levels of pro-inflammatory cytokines TNFα, IL-6, and IL-1β in the serum of WT (n = 12) and <italic>Bad</italic><sup>−/−</sup> (n = 12) mice in CIA model were determined by ELISA. All data are presented as mean ± SEM, and dots represent individual mice. Significant difference was analyzed by Mann–Whitney <italic>U</italic>-test (<bold>A</bold>) or unpaired Student’s <italic>t</italic>-test (<bold>C, E, F, and G</bold>), *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig1">Figure 1A,C,E,F, and G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1 .</label><caption><title>BAD deficiency does not affect osteoclast activation in vitro.</title><p>(<bold>A</bold>) TRAP staining and quantification of TRAP<sup>+</sup> multinucleated cells (MNCs) per field in the joints of wild-type (WT) (n = 5) and <italic>Bad</italic><sup>−/−</sup> (n = 6) mice in CIA model. Scale bar, 50 μm. (<bold>B</bold>) Relative mRNA expression levels of osteoclast specific markers (<italic>TRAP</italic> and <italic>Ctsk</italic>) in the joints of WT (n = 7) and <italic>Bad</italic><sup>−/−</sup> (n = 9) mice in CIA model. (<bold>C</bold>) WT and <italic>Bad</italic><sup>−/−</sup>bone marrow-derived macrophages (BMDMs) were treated with M-CSF and RANKL to induce osteoclast differentiation, osteoclasts were detected by TRAP staining. Scale bar, 50 μm. The number of TRAP positive MNCs per field was quantified. (<bold>D</bold>) Relative mRNA expression levels of <italic>TRAP</italic> and <italic>Ctsk</italic> in BMDMs treated with M-CSF and RANKL. Data in (<bold>C and D</bold>) represent two individual experiments with similar results. All data are presented as mean ± SEM, dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, *p&lt;0.05; **p&lt;0.01.</p><p> <supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Bad</italic> loss leads to accumulation of macrophages and B cells but not CD4<sup>+</sup> T cells in CIA</title><p>We wanted to know whether <italic>Bad</italic> loss affects macrophages, which have a crucial role in inflammation in CIA, and the infiltration of lymphocytes in synovium, as B cell-mediated humoral immunity and T cell-mediated cellular immunity are known to play important roles in the pathogenesis of RA (<xref ref-type="bibr" rid="bib35">McInnes and Schett, 2011</xref>). Flow cytometry analysis showed accumulation of macrophages was significantly increased in the synovium of <italic>Bad</italic><sup>−/−</sup> mice compared with WT littermates in CIA model (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>). The percentage of synovial B cells was also increased in <italic>Bad</italic><sup>−/−</sup> mice with CIA (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C,D</xref>), consistent with upregulated collagen II-specific antibodies production in the serum of <italic>Bad</italic><sup>−/−</sup> mice in CIA model (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). However, the percentage of synovial CD4<sup>+</sup> T cells was comparable between <italic>Bad</italic><sup>−/−</sup> mice and WT littermates (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E,F</xref>). Consistently, <italic>Bad</italic> loss did not affect expression levels of CD4<sup>+</sup> T cell-associated cytokines including IFN-γ, IL-4, and IL-17 between WT and <italic>Bad</italic><sup>−/−</sup> mice with CIA, although increased expression of IL-21 that is known to promote B cell differentiation and proliferation (<xref ref-type="bibr" rid="bib13">Dienz et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Liu and King, 2013</xref>; <xref ref-type="bibr" rid="bib70">Zotos et al., 2010</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>). By contrast, the percentages of both CD4<sup>+</sup> T cells and B cells in spleen and lymph nodes (LNs) had no significant differences (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). These results suggest that <italic>Bad</italic> loss results in accumulation of macrophages and B cells but not CD4<sup>+</sup> T cells in synovium in mice with CIA.</p></sec><sec id="s2-3"><title><italic>Bad</italic>-deficient B cells alone are not sufficient to promote the development of CIA</title><p>To determine the role of <italic>Bad-</italic>deficient B cells in the development of CIA, bone marrow cells isolated from <italic>Bad</italic><sup>−/−</sup> mice and WT littermates were mixed with the bone marrow cells isolated from mature B cell-deficient μMT mice at a ratio of 1:4, respectively, and then transferred into lethally irradiated μMT mice to establish CIA model (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). The percentage of B cells in peripheral blood was comparable between μMT mice transferred with WT (μMT:WT mice) and <italic>Bad</italic><sup>−/−</sup> (μMT:<italic>Bad</italic><sup>−/−</sup> mice) bone marrow cells after transplantation (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). The incidence and severity of CIA were similar between μMT:WT mice and μMT:<italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C,D</xref>). In support of this notion, histopathological analysis showed that there was no significant difference in synovitis, pannus formation, as well as bone and cartilage destruction between these two different groups of mice (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3E,F</xref>). Consistently, <italic>Bad</italic> loss did not affect the autoantibody production, as measured by ELISA that detects anti-dsDNA IgG level in serum of 5-month-old WT and <italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3G</xref>). Thus, <italic>Bad-</italic>deficient B cells alone are not sufficient to promote the development of CIA. Most likely, the function of B cells in <italic>Bad<sup>−/−</sup></italic> mice with CIA is augmented extrinsically, thereby contributing to CIA pathogenesis.</p></sec><sec id="s2-4"><title><italic>Bad</italic> loss protects synovial macrophages from apoptosis in CIA</title><p>We hypothesized that <italic>Bad</italic> loss reduces apoptosis of synovial cells in mice with CIA. Immunoblotting analysis of cleaved Caspase-3 (cCasp-3), one of the executioner caspases in BAD-mediated apoptosis pathway, in the joint extracts of WT and <italic>Bad</italic><sup>−/−</sup> mice with CIA revealed that the Casp-3 activity was decreased in <italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>). Immunofluorescence double staining of TUNEL with anti-Vimentin (marker of fibroblast), anti-CD4 (marker of CD4<sup>+</sup> T cell), or anti-CD45R (marker of B cell) revealed that there was no significant difference in cell death in fibroblasts, CD4<sup>+</sup> T cells, or B cells in the synovium of <italic>Bad</italic><sup>−/−</sup> and WT littermate mice in CIA model (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B–D</xref>). By contrast, death of macrophage as detected by TUNEL and anti-F4/80 double staining was significantly reduced in the synovium of <italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4E</xref>). Consistently, immunofluorescence double staining of anti-F4/80 and anti-cleaved Casp-3 revealed that macrophage apoptosis in sublining was significantly reduced, which was most likely responsible for accumulation of macrophages in the synovium of <italic>Bad</italic><sup>−/−</sup> mice with CIA (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Consistently, flow cytometry analysis of cleaved caspase-3 positive synovial macrophages isolated from arthritic joints of WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model showed reduced ratio of apoptotic macrophages in the joints of <italic>Bad</italic><sup>−/−</sup> mice compared with WT mice in CIA model (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>). In addition, flow cytometry analysis of Annexin V showed reduced ratio of apoptotic macrophages in the joints of <italic>Bad</italic><sup>−/−</sup> mice in CIA model (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>). By contrast, there was no significant difference in the ratio of apoptotic B cells, CD4<sup>+</sup> T cells, or synovial fibroblasts in arthritic joints of WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model, analyzed by either cleaved caspase-3 (<xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>) or Annexin V (<xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref>) flow cytometry assay. These results indicate that <italic>Bad</italic> loss mainly affects macrophage apoptosis, while apoptosis of other cell types appear to be less affected. Suppression of macrophage apoptosis may not only promote inflammation but also further stimulate B cell proliferation, thereby aggravating CIA in <italic>Bad</italic><sup>−/−</sup> mice.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Bad</italic> loss protects synovial macrophages from apoptosis in collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Double staining of anti-F4/80 and anti-cleaved Casp-3 in the ankle joint sections of wild-type (WT) and <italic>Bad</italic><sup>−/−</sup> mice in CIA model. L: lining; SL: Sublining. Scale bar, 25 μm. (<bold>B</bold>) Quantification of the number of cleaved Casp-3 positive macrophage and total macrophage per region of interest (ROI) in the ankle joint sections of WT (n = 4) and <italic>Bad</italic><sup>−/−</sup> (n = 6) mice in CIA model. (<bold>C</bold>) Apoptotic synovial macrophages from WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model were analyzed by flow cytometry by staining cleaved Casp-3. (<bold>D</bold>) Quantification of the ratio of cleaved Casp-3 positive synovial macrophages in WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 6) mice in CIA model. (<bold>E</bold>) Apoptotic cell death of WT and <italic>Bad</italic><sup>−/− </sup>bone marrow-derived macrophages (BMDMs) pretreated with PS1145 (10 μM) for 2 hr, followed by stimulation with TNFα (5 ng/ml) for various times as indicated, was analyzed by flow cytometry. (<bold>F</bold>) Quantification of apoptotic BMDMs for various time points as indicated. Data in (<bold>E and F</bold>) represent two individual experiments with similar results. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, **p&lt;0.01; ***p&lt;0.001.</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig2">Figure 2B,D, and F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig2-data1-v1.xlsx"/></supplementary-material> </p><p> <supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s7">7</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig2-data2-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The percentages of macrophage, B cell, and CD4<sup>+</sup> T cell in synovium of wild-type (WT) and <italic>Bad</italic><sup>−/−</sup> mice in collagen-induced arthritis (CIA) model.</title><p>(<bold>A, C, and E</bold>) The percentages of macrophage (CD11b<sup>+</sup> F4/80<sup>+</sup>) (<bold>A</bold>), B cell (CD45<sup>+</sup> B220<sup>+</sup>) (<bold>C</bold>), and CD4<sup>+</sup> T cell (CD45<sup>+</sup> CD4<sup>+</sup>) (<bold>E</bold>) in the synovium of WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model were determined by flow cytometry. (<bold>B, D, and F</bold>) Quantification of the percentages of macrophage (<bold>B</bold>), B cell (<bold>D</bold>), and CD4<sup>+</sup> T cell (<bold>F</bold>) in the synovium of WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 6) mice in CIA model. (<bold>G</bold>) Relative mRNA expression levels of cytokines secreted by CD4<sup>+</sup> T cell subtypes in the joints of WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 9) mice in CIA model. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>The number of B cell and CD4<sup>+</sup> T cell in spleen and lymph node (LN) has no significant difference between wild-type (WT) and <italic>Bad</italic><sup>−/−</sup> mice in collagen-induced arthritis (CIA) model.</title><p>(<bold>A</bold>) The percentages of B cell and CD4<sup>+</sup> T cell in the spleen of WT and <italic>Bad</italic><bold><sup>−/−</sup></bold> mice in CIA model were determined by flow cytometry. (<bold>B</bold>) The percentages of B cell and CD4<sup>+</sup> T cell in the LN of WT and <italic>Bad</italic><bold><sup>−/−</sup></bold> mice in CIA model were determined by flow cytometry. All data are presented as mean ± SEM, dots represent individual mice, and n = 6 for each group. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title><italic>Bad</italic>-deficient B cells alone are not sufficient to promote collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) The experimental design diagram for bone marrow transplantation in μMT mice followed by CIA model. (<bold>B</bold>) The percentages of B cell in the peripheral blood (6 weeks after transplantation) of μMT:wild-type (WT) (n = 6) and μMT:<italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 6) mice were analyzed by flow cytometry. WT mice served as positive control and μMT mice served as negative control. (<bold>C</bold>) Representative photographs of the hind paws from μMT:WT mice and μMT:<italic>Bad</italic><bold><sup>−/−</sup></bold> mice in CIA model. (<bold>D</bold>) Incidence and clinical scores of μMT:WT (n = 16) and μMT:<italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 16) mice in CIA model. (<bold>E</bold>) H &amp; E and Safranin O staining in ankle joint sections of μMT:WT and μMT:<italic>Bad</italic><bold><sup>−/−</sup></bold> mice in CIA model, ankle joints were harvested 63 days after primary immunization. Scale bar, 100 μm. (<bold>F</bold>) Evaluation of synovitis, pannus, and erosion of ankle joints from μMT:WT (n = 12) and μMT:<italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 12) mice in CIA model. (<bold>G</bold>) Anti-dsDNA IgG levels in the serum of 5-month-old WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 5) mice were detected by ELISA. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by Mann–Whitney <italic>U</italic>-test (<bold>D</bold>) or unpaired Student’s <italic>t</italic>-test (<bold>B, F, and G</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title><italic>Bad</italic> loss inhibits apoptosis in macrophages but not in fibroblasts, CD4<sup>+</sup> T cells, or B cells in collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Immunoblotting analysis of caspase-3, cCasp-3, and BAD in ankle joint extracts of immunized wild-type (WT) (n = 3) and <italic>Bad<sup>−/−</sup></italic> (n = 3) mice. (<bold>B</bold>) Double staining of anti-Vimentin (fibroblast marker) and TUNEL in ankle sections of WT (n = 4) and <italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 6) mice in CIA model. The number of Vimentin and TUNEL double positive cells per field was quantified. (<bold>C</bold>) Double staining of anti-CD4 (CD4<sup>+</sup> T cell marker) and TUNEL in ankle sections of WT (n = 4) and <italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 6) mice in CIA model. The number of CD4 and TUNEL double positive cells per field was quantified. (<bold>D</bold>) Double staining of anti-CD45R (B cell marker) and TUNEL in ankle sections of WT (n = 4) and <italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 6) mice in CIA model. The number of CD45R and TUNEL double positive cells per field was quantified. (<bold>E</bold>) Double staining of anti-F4/80 (macrophage marker) and TUNEL in ankle sections of WT (n = 4) and <italic>Bad</italic><bold><sup>−/−</sup></bold> (n = 6) mice in CIA model. The number of F4/80 and TUNEL double positive cells per field was quantified. Scale bar, 50 μm. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title><italic>Bad</italic> loss protects synovial macrophages from apoptosis in collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Apoptotic synovial macrophages from wild-type (WT) and <italic>Bad</italic><sup>−/−</sup> mice in CIA model were analyzed by flow cytometry by staining Annexin V. (<bold>B</bold>) Quantification of the ratio of Annexin V positive synovial macrophages in WT (n = 6) and <italic>Bad</italic><sup>−/−</sup> (n = 6) mice in CIA model. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp5-v1.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title><italic>Bad</italic> loss does not significantly affect the apoptosis of B cells, CD4<sup>+</sup> T cells, or synovial fibroblasts in collagen-induced arthritis (CIA) detected by cleaved Casp-3 staining.</title><p>(<bold>A, C, and E</bold>) Apoptotic synovial B cells (<bold>A</bold>), CD4<sup>+</sup> T cells (<bold>C</bold>), and fibroblasts (<bold>E</bold>) from wild-type (WT) and <italic>Bad</italic><sup>−/−</sup> mice in CIA model were analyzed by flow cytometry by staining cleaved Casp-3. (<bold>B, D, and F</bold>) Quantification of the apoptotic B cells (<bold>B</bold>), CD4<sup>+</sup> T cells (<bold>D</bold>), and fibroblasts (<bold>F</bold>). All data are presented as mean ± SEM, dots represent individual mice, and n = 6 for each group. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp6-v1.tif"/></fig><fig id="fig2s7" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 7.</label><caption><title><italic>Bad</italic> loss does not significantly affect the apoptosis of B cells, CD4<sup>+</sup> T cells, or synovial fibroblasts in collagen-induced arthritis (CIA) detected by Annexin V staining.</title><p>(<bold>A, C, and E</bold>) Apoptotic synovial B cells (<bold>A</bold>), CD4<sup>+</sup> T cells (<bold>C</bold>), and fibroblasts (<bold>E</bold>) from WT and <italic>Bad</italic><sup>−/−</sup> mice in CIA model were analyzed by flow cytometry by staining Annexin V. (<bold>B, D, and F</bold>) Quantification of the apoptotic B cells (<bold>B</bold>), CD4<sup>+</sup> T cells (<bold>D</bold>), and fibroblasts (<bold>F</bold>). All data are presented as mean ± SEM, dots represent individual mice, and n = 6 for each group. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig2-figsupp7-v1.tif"/></fig></fig-group><p>Next we wanted to know whether BAD involves in TNFα-induced macrophage apoptosis, as RA is a chronic inflammatory disease which has consistent expression of TNFα, while inactivation of BAD by IKK can inhibit TNFα-induced apoptosis (<xref ref-type="bibr" rid="bib65">Yan et al., 2013</xref>). When WT and <italic>Bad</italic><sup>−/−</sup> BMDMs were pretreated with IKK-specific inhibitor PS1145 to block TNFα-induced IKK activation, <italic>Bad</italic><sup>−/−</sup> BMDMs were resistant to TNFα-induced apoptosis in vitro, as analyzed by flow cytometry (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>), indicating <italic>Bad</italic> loss can protect synovial macrophages from TNFα-induced apoptosis, thereby augmenting CIA.</p></sec><sec id="s2-5"><title><italic>Bad-</italic>deficient macrophages sufficiently aggravate CIA</title><p>To determine the role of <italic>Bad</italic> loss in macrophages in the development of CIA, bone marrow cells isolated from WT or <italic>Bad</italic><sup>−/−</sup> mice (both on CD45.2 background) were transferred into lethally irradiated WT recipient mice (CD45.1 background), which had a complete and stable chimerism with donor mice in bone marrow after transplantation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The recipient mice were subjected to CIA 6 weeks after transplantation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), among which the mice transferred with <italic>Bad</italic><sup>−/−</sup> bone marrow cells (CD45.1:<italic>Bad</italic><sup>−/−</sup> mice) displayed more severe arthritis and higher incidence and clinical score than the mice transferred with WT bone marrow cells (CD45.1:WT mice) (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>). Histopathological analysis showed increased synovitis, pannus formation, as well as cartilage and bone destruction in CD45.1:<italic>Bad</italic><sup>−/−</sup> mice compared with CD45.1:WT mice (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref>). The number of synovial sublining macrophages in CD45.1:<italic>Bad</italic><sup>−/−</sup> mice was also increased compared with that in CD45.1:WT mice, while apoptosis of synovial sublining macrophages in CD45.1:<italic>Bad</italic><sup>−/−</sup> mice was significantly reduced, as analyzed by double staining of anti-F4/80 and anti-cleaved Casp-3 (<xref ref-type="fig" rid="fig3">Figure 3F,G</xref>). Thus, <italic>Bad</italic>-deficient macrophages are sufficient to promote the development of CIA, suggesting that macrophage function is augmented intrinsically in <italic>Bad<sup>−/−</sup></italic> mice to contribute to CIA pathology.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Bad-</italic>deficient macrophages sufficiently aggravate collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) The experimental design diagram for bone marrow transplantation in CD45.1 background mice followed by CIA model. (<bold>B</bold>) Representative photographs of the hind paws from CD45.1:WT and CD45.1:<italic>Bad</italic><sup>−/−</sup> mice in CIA model. (<bold>C</bold>) Incidence and clinical scores of CD45.1:WT (n = 15) and CD45.1:<italic>Bad</italic><sup>−/−</sup> (n = 17) mice in CIA model. (<bold>D</bold>) H &amp; E and Safranin O staining in ankle joint sections of CD45.1:WT and CD45.1:<italic>Bad</italic><sup>−/−</sup> mice in CIA model, ankle joints were harvested 63 days after primary immunization. Scale bar, 100 μm. (<bold>E</bold>) Evaluation of synovitis, pannus, and erosion of ankle joints from CD45.1:WT (n = 15) and CD45.1:<italic>Bad</italic><sup>−/−</sup> (n = 17) mice in CIA model. (<bold>F</bold>) Double staining of anti-F4/80 and anti-cleaved Casp-3 in the ankle joint sections of CD45.1:WT and CD45.1:<italic>Bad</italic><sup>−/−</sup> mice in CIA model. Scale bar, 25 μm. (<bold>G</bold>) Quantification of the number of cleaved Casp-3 positive macrophage and total macrophage per field in the ankle joint sections of CD45.1:WT (n = 7) and CD45.1:<italic>Bad</italic><sup>−/−</sup> (n = 9) mice in CIA model. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by Mann–Whitney <italic>U</italic>-test (<bold>C</bold>) or unpaired Student’s <italic>t</italic>-test (<bold>E and G</bold>), *p&lt;0.05; **p&lt;0.01.</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig3">Figure 3C,E, and G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig3-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Efficiency of bone marrow transplantation in CD45.1 mice.</title><p>(<bold>A</bold>) The percentages of overall CD45.2 cells in the peripheral blood (4 weeks after transplantation) of CD45.1:WT and CD45.1:<italic>Bad</italic><bold><sup>−/−</sup></bold> mice were analyzed by flow cytometry. (<bold>B</bold>) The percentages of overall CD45.2 cells in the peripheral blood (8 weeks after transplantation) of CD45.1:WT and CD45.1:<italic>Bad</italic><bold><sup>−/−</sup></bold> mice were analyzed by flow cytometry. (<bold>C</bold>) The percentages of CD45.2 myeloid cells (gated by Mac1 and Gr1) in the peripheral blood (4 weeks after transplantation) of CD45.1:WT and CD45.1:<italic>Bad</italic><bold><sup>−/−</sup></bold> mice were analyzed by flow cytometry. All data are presented as mean ± SEM, dots represent individual mice, and n = 5 mice for each group. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test.</p><p> <supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>The pro-apoptotic activity of BAD was suppressed in synovial sublining macrophages in CIA</title><p>We next determined how the pro-apoptotic activity of BAD is regulated in synovial sublining macrophages in mice with CIA. There was no significant difference in BAD protein level in total joint extracts between control (non-arthritic) and arthritic joints of WT mice in CIA (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). By contrast, phosphorylation of BAD at the ‘regulatory serines’ (Ser112, Ser136, and Ser155), indicative of BAD inactivation (<xref ref-type="bibr" rid="bib12">Datta et al., 2002</xref>) was profoundly increased in arthritic joints compared with control joints (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Immunohistochemistry (IHC) staining revealed that Ser136-phosphorylated BAD [pBAD(S136)] was significantly increased mainly in the synovial sublining layer of arthritic joint compared with that in the control joint (<xref ref-type="fig" rid="fig4">Figure 4B,C</xref>). Furthermore, the cells with strong pBAD(S136) signal were mostly localized in the cartilage-pannus junction areas (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), which are often infiltrated by macrophages (<xref ref-type="bibr" rid="bib54">Tak and Bresnihan, 2000</xref>). In support of this notion, immunofluorescence double staining of anti-pBAD(S136) along with different cell markers revealed that pBAD(S136) mainly located in macrophages (F4/80<sup>+</sup>), but not T cells (CD3<sup>+</sup>), B cells (CD45R<sup>+</sup>) or fibroblasts (Vimentin<sup>+</sup>) (<xref ref-type="fig" rid="fig4">Figure 4D,E</xref>). This was not the result of cell-type specific expression of BAD (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), and little pBAD(S136) signal was found in these cell types in non-arthritic joints (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). More importantly, pBAD(S136)<sup>+</sup> macrophages mainly located in the sublining layer of arthritic joint synovium (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). These data indicate that inactivation of BAD is responsible for, at least in part, the resistance of infiltrated macrophages to apoptosis in CIA.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The pro-apoptotic activity of BAD was suppressed in synovial sublining macrophages in collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Immunoblotting analysis of pBAD(S112), pBAD(S136), pBAD(S155), and BAD in ankle joints extracts of wild-type (WT) control (non-arthritic) and arthritic mice in CIA model (n = 3). (<bold>B</bold>) Immunohistochemistry staining of anti-pBAD(S136) in the synovium of WT control and arthritic mice in CIA model, <italic>Bad</italic><sup>−/−</sup> mice serve as control. Scale bar, 50 μm. (<bold>C</bold>) Quantification of the number of pBAD(S136) positive cells per field (n = 4). (<bold>D</bold>) Double staining of anti-pBAD(S136) with T cell marker anti-CD3, B cell marker anti-CD45R, macrophage marker anti-F4/80, or synovial fibroblast marker anti-Vimentin respectively in the synovium of WT arthritic mice in CIA model. Scale bar, 25 μm. (<bold>E</bold>) Quantification of percentages of pBAD(S136) positive cells in total cells per field of different cell types (n = 3). (<bold>F</bold>) Double staining of anti-pBAD(S136) and anti-F4/80 in the synovium of WT control and arthritic mice in CIA model. Scale bar, 25 μm. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test (<bold>C</bold>) or one-way ANOVA test (<bold>E</bold>), **p&lt;0.01; ***p&lt;0.001.</p><p> <supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig4">Figure 4C and E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig4-data1-v1.xlsx"/></supplementary-material> </p><p> <supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig4-data2-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The expression of BAD is not cell-type specific in arthritic joints in collagen-induced arthritis (CIA) model.</title><p>(<bold>A</bold>) Double staining of anti-BAD with T cell marker anti-CD3, B cell marker anti-CD45R, macrophage marker anti-F4/80, or synovial fibroblast marker anti-Vimentin respectively in the synovium of wild-type (WT) arthritic mice in CIA model. Scale bar, 25 μm. (<bold>B</bold>) Quantification of percentages of BAD positive cells in total cells per field of different cell types (n = 3). Data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by one-way ANOVA test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>pBAD staining in various cell types of non-arthritic joints.</title><p>(<bold>A</bold>) Double staining of anti-pBAD(S136) with T cell marker anti-CD3, B cell marker anti-CD45R, macrophage marker anti-F4/80 or synovial fibroblast marker anti-Vimentin, respectively, in the synovium of WT non-arthritic mice. Scale bar, 25 μm. (<bold>B</bold>) Quantification of percentages of pBAD(S136) positive cells in total cells per field of different cell types (n = 3). Data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by one-way ANOVA test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig4-figsupp2-v1.tif"/></fig></fig-group><p>To elucidate the signaling pathways that lead to inactivation of BAD in synovial macrophages in CIA, we examined the activity of Akt and IKK in the synovial macrophages in the control and arthritic joints of WT mice with CIA, since Akt is a known BAD(S136) kinase upon stimulation by growth factors and survival factors and is upregulated in the synovium of RA for survival of synovial cells (<xref ref-type="bibr" rid="bib11">Datta et al., 1997</xref>; <xref ref-type="bibr" rid="bib21">Jiao et al., 2018</xref>), while IKK is known to phosphorylate BAD at Ser26, which is a prerequisite for BAD to be phosphorylated at Ser112, Ser136, and Ser155 upon stimulation by TNFα (<xref ref-type="bibr" rid="bib65">Yan et al., 2013</xref>), which is the key pro-inflammatory cytokine that induces inflammation in RA (<xref ref-type="bibr" rid="bib60">van Schouwenburg et al., 2013</xref>). Immunofluorescence double staining of anti-pAkt and anti-F4/80 revealed that macrophages in the sublining synovium of arthritic joints had significantly increased activation of Akt compared with that in control joints (<xref ref-type="fig" rid="fig5">Figure 5A,C</xref>), so was activation of IKK (<xref ref-type="fig" rid="fig5">Figure 5B,D</xref>). Consistently, phosphorylation of Akt and IKK, as well as the protein levels of PDGF and VEGF were significantly increased in the arthritic joint extracts (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Taken together, activation of Akt and IKK are responsible for, at least in part, phosphorylation and inactivation of BAD in infiltrated sublining macrophages in CIA model.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Akt and IKK activation was increased in synovial sublining macrophage in collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Double staining of anti-pAkt and anti-F4/80 in the synovium of wild-type (WT) control and arthritic mice in CIA model. Scale bar, 25 μm. (<bold>B</bold>) Double staining of anti-pIKK and anti-F4/80 in the synovium of WT control and arthritic mice in CIA model. Scale bar, 25 μm. (<bold>C</bold>) Quantification of the number of pAkt and F4/80 double positive cells per field in the synovium of WT control (n = 4) and arthritic (n = 4) mice in CIA model. (<bold>D</bold>) Quantification of the number of pIKK and F4/80 double positive cells per field in the synovium of WT control (n = 4) and arthritic (n = 4) mice in CIA model. (<bold>E</bold>) Immunoblotting analysis of the protein levels of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), pAkt, Akt, pIKK, and IKK in the joint extracts of WT non-arthritic (n = 3) and arthritic (n = 3) mice in CIA model. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, **p&lt;0.01; ***p&lt;0.001.</p><p> <supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig5">Figure 5C and D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig5-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig5-v1.tif"/></fig></sec><sec id="s2-7"><title>Inactivation of BAD in synovial sublining macrophages in TNF-Tg mice</title><p>We also determined the pathological function of BAD in TNF-Tg mice, another murine model of experimental arthritis in which overexpression of human TNFα leads to inflammatory-erosive arthritis (<xref ref-type="bibr" rid="bib29">Li and Schwarz, 2003</xref>). Histopathological analysis showed increased synovitis, pannus formation, as well as cartilage and bone destruction in the joints of 3-month-old TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice compared with TNF-Tg littermates (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>), suggesting that <italic>Bad</italic> loss also exacerbates experimental arthritis in TNF-Tg model. IHC staining revealed that pBAD(S136) was significantly increased in the synovial sublining layer of TNF-Tg mice compared with that in the control mice (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>) and was co-stained with anti-F4/80 (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), suggesting that pBAD(S136)<sup>+</sup> macrophages were mainly increased in the synovial sublining layer. More importantly, the macrophage apoptosis, as revealed by anti-F4/80 and anti-cleaved Casp-3 double staining, was significantly reduced in the synovial sublining layer in TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice compared with the control TNF-Tg littermates, correlating with increased macrophage numbers in synovial sublining layer in TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Consistently, flow cytometry analysis of cleaved caspase-3 also revealed reduced macrophage apoptosis under the same conditions (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref>). These results suggest that BAD phosphorylation and inactivation is a shared mechanism for apoptosis resistance of synovial sublining macrophage in two different experimental arthritis murine models.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>Bad</italic> loss aggravates arthritis in TNFα transgenic (TNF-Tg) mouse model.</title><p>(<bold>A</bold>) H &amp; E and Safranin O staining in ankle joint sections of 3-month-old wild-type (WT), <italic>Bad</italic><sup>−/−</sup>, TNF-Tg, and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice. Scale bar, 500 μm; magnified inset, 100 μm. (<bold>B</bold>) Evaluation of synovitis, pannus, and erosion of ankle joints of TNF-Tg (n = 10) and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> (n = 10) mice. (<bold>C</bold>) Immunohistochemistry staining of anti-pBAD(S136) in the synovium of 3-month-old WT, TNF-Tg, and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice. Scale bar, 50 μm. (<bold>D</bold>) Quantification of the number of pBAD(S136) positive cells per field (n = 3). (<bold>E</bold>) Double staining of anti-pBAD(S136) and anti-F4/80 in the synovium of 3-month-old WT control and TNF-Tg mice. Scale bar, 25 μm. (<bold>F</bold>) Apoptotic synovial macrophages from TNF-Tg and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice were analyzed by flow cytometry by staining cleaved Casp-3. (<bold>G</bold>) Quantification of the ratio of cleaved Casp-3 positive synovial macrophages in TNF-Tg (n = 6) and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> (n = 6) mice. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p><p> <supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig6">Figure 6B,D, and G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig6-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>Bad</italic> loss prevents sublining macrophages from apoptosis in TNFα transgenic (TNF-Tg) mouse model.</title><p>(<bold>A</bold>) Double staining of anti-F4/80 and anti-cleaved Casp-3 in the ankle joint sections of 3-month-old TNF-Tg and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> mice. Scale bar, 25 μm. (<bold>B</bold>) Quantification of the number of cleaved Casp-3 positive macrophage and total macrophage per field in the ankle joint sections of TNF-Tg (n = 4) and TNF-Tg/<italic>Bad</italic><sup>−/−</sup> (n = 4) mice. All data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test, *p&lt;0.05; **p&lt;0.01.</p><p> <supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title><italic>Bad<sup>3SA/3SA</sup></italic> mice are resistant to CIA</title><p>To demonstrate phosphorylation-mediated inactivation of BAD contributes to the development of experimental arthritis, we performed CIA in <italic>Bad<sup>3SA/3SA</sup></italic> knockin mice, in which the regulatory serine sites were mutated to alanines so that the resultant BAD mutant can no longer be phosphorylated and inactivated (<xref ref-type="bibr" rid="bib12">Datta et al., 2002</xref>; <xref ref-type="fig" rid="fig7">Figure 7A,B</xref>). <italic>Bad<sup>3SA/3SA</sup></italic> mice displayed very lower incidence and significantly reduced severity of arthritis compared with WT littermates in CIA model (<xref ref-type="fig" rid="fig7">Figure 7C,D</xref>). Histopathological analysis showed significantly decreased synovitis, pannus formation, as well as cartilage and bone destruction in <italic>Bad<sup>3SA/3SA</sup></italic> mice (<xref ref-type="fig" rid="fig7">Figure 7E,F</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>Bad<sup>3SA/3SA</sup></italic> mice are resistant to collagen-induced arthritis (CIA).</title><p>(<bold>A</bold>) Immunoblotting analysis of pBAD(S112), pBAD(S136), pBAD(S155), and BAD in the joint extracts of wild-type (WT; n = 3) and <italic>Bad</italic><sup>3SA/3SA</sup> (n = 3) mice in CIA model. (<bold>B</bold>) Representative IHC staining of pBAD(S136) in the synovium of immunized WT and <italic>Bad</italic><sup>3SA/3SA</sup> mice. Scale bar, 50 μm. (<bold>C</bold>) Representative photographs of the hind paws of WT and <italic>Bad</italic><sup>3SA/3SA</sup> mice in CIA model. (<bold>D</bold>) Incidence and clinical scores of WT (n = 13) and <italic>Bad</italic><sup>3SA/3SA</sup> (n = 14) mice in CIA model. (<bold>E</bold>) H &amp; E and Safranin O staining in ankle joint sections of WT and <italic>Bad</italic><sup>3SA/3SA</sup> mice in CIA model. Ankle joints were harvested 63 days after primary immunization. Scale bar, 100 μm. (<bold>F</bold>) Evaluation of synovitis, pannus, and erosion of ankle joints from WT (n = 13) and <italic>Bad</italic><sup>3SA/3SA</sup> (n = 14) mice in CIA model. (<bold>G</bold>) Immunoblotting analysis of caspase-3 and cleaved Casp-3 in ankle joints of immunized WT (n = 3) and <italic>Bad</italic><sup>3SA/3SA</sup> (n = 3) mice. (<bold>H</bold>) Double staining of anti-F4/80 and anti-cleaved Casp-3 in the sublining area of ankle joint sections of WT and <italic>Bad</italic><sup>3SA/3SA</sup> mice in CIA model. Scale bar, 50 μm. (<bold>I</bold>) Quantification of the cleaved Casp-3-positive macrophage and number of total macrophage per field in the ankle joint sections of WT (n = 6) and <italic>Bad</italic><sup>3SA/3SA</sup> (n = 6) mice in CIA model. All of the data are presented as mean ± SEM; dots represent individual mice. Significant difference was analyzed by Mann–Whitney <italic>U</italic>-test (<bold>D</bold>) or unpaired Student’s <italic>t</italic>-test (<bold>F and I</bold>), *p&lt;0.05; **p&lt;0.01.</p><p> <supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig7">Figure 7D,F, and I</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig7-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig7-v1.tif"/></fig><p>We next determined whether the decreased incidence and reduced severity of CIA in <italic>Bad<sup>3SA/3SA</sup></italic> mice is the result of increased apoptosis of synovial sublining macrophages. Immunoblotting analysis showed increased protein level of cleaved Casp-3 in joint extracts of <italic>Bad<sup>3SA/3SA</sup></italic> mice compared with WT littermates in CIA model (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Furthermore, immunofluorescence double staining of anti-F4/80 with anti-cleaved Casp-3 revealed that apoptosis of synovial sublining macrophage was significantly increased, consistent with decreased synovial macrophage number in <italic>Bad<sup>3SA/3SA</sup></italic> mice compared with that in WT littermates (<xref ref-type="fig" rid="fig7">Figure 7H,I</xref>). Taken together, these results demonstrate that phosphorylation-mediated inactivation of BAD is critical for synovial sublining macrophages survival and the development of CIA.</p></sec><sec id="s2-9"><title>Inactivation of BAD in synovial sublining macrophages in patients with RA</title><p>We wondered whether BAD also plays an important role in human RA. H &amp; E staining showed increased infiltration of inflammatory cells in the synovial sections of RA patients compared with osteoarthritis (OA) patients (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), consistent with previous reports (<xref ref-type="bibr" rid="bib23">Kennedy et al., 1988</xref>). IHC staining of anti-pBAD (S99, equivalent to S136 in mouse) revealed that phosphorylation of human BAD (hBAD) at Ser99 was significantly higher in sublining layer of synovium of RA patients compared with that in OA patients (<xref ref-type="fig" rid="fig8">Figure 8A,B</xref>), consistent with the results in mouse arthritic joints (<xref ref-type="fig" rid="fig4">Figure 4B,C</xref>). Immunofluorescence double staining of anti-pBAD(S99) along with the markers of several synovial cell types including macrophage (CD68<sup>+</sup>), B cell (CD20<sup>+</sup>), T cell (CD3<sup>+</sup>), and fibroblast (Vimentin<sup>+</sup>) revealed that pBAD(S99) was mainly located in macrophages in sublining but not B cells, T cells, or fibroblasts (<xref ref-type="fig" rid="fig8">Figure 8C–E</xref>), consistent with the observations in CIA mice (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). This was not the result of cell-type-specific expression of BAD (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). These results demonstrate that phosphorylation of BAD was increased in macrophages in sublining synovium of RA patients, thereby contributing to the apoptotic resistance of pro-inflammatory macrophages and pathology in RA patients.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>BAD phosphorylation is increased in the synovial sublining macrophages of rheumatoid arthritis (RA) patients.</title><p>(<bold>A</bold>) H &amp; E and pBAD(S99) immunohistochemistry staining of the synovium specimen sections of patients with OA and RA. Scale bar, 100 μm. (<bold>B</bold>) Quantification of pBAD(S99)-positive cells per field in the synovial specimen sections of patients with OA (n = 5) and RA (n = 5). (<bold>C</bold>) Double staining of anti-pBAD(S99) with T cell marker anti-CD3, B cell marker anti-CD20, macrophage marker anti-CD68 or synovial fibroblast marker anti-Vimentin in serial synovial specimen sections of patients with RA. Scale bar, 100 μm. (<bold>D</bold>) Quantification of the percentage of pBAD(S99)-positive cells in total cells per field of different cell types (n = 5). (<bold>E</bold>) Double staining of anti-pBAD(S99) and anti-F4/80 in the synovial specimen sections of patients with OA and RA. Scale bar, 25 μm. All data are presented as mean ± SEM; dots represent individual human samples. Significant difference was analyzed by unpaired Student’s <italic>t</italic>-test (<bold>B</bold>) or one-way ANOVA test (<bold>D</bold>), **p&lt;0.01, ***p&lt;0.001.</p><p> <supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig8">Figure 8B and D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig8-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>The expression of BAD is not cell-type specific in synovium of rheumatoid arthritis (RA) patients.</title><p>(<bold>A</bold>) Double staining of BAD with T cell marker anti-CD3, B cell marker anti-CD20, macrophage marker anti-CD68, or synovial fibroblast marker anti-Vimentin in serial synovial specimen sections of patients with RA. Scale bar, 100 μm. (<bold>B</bold>) Quantification of percentages of BAD positive cells in total cells per field of different cell types (n = 3). Data are presented as mean ± SEM; dots represent individual human samples. Significant difference was analyzed by one-way ANOVA test.</p><p> <supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>Source data for graphs in <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56309-fig8-figsupp1-data1-v1.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56309-fig8-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>It has long been thought that the resistance of infiltrating synovial sublining macrophages to apoptosis plays a central role in RA pathogenesis (<xref ref-type="bibr" rid="bib4">Bresnihan et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Haringman et al., 2005</xref>; <xref ref-type="bibr" rid="bib58">Udalova et al., 2016</xref>). Although several anti- and pro-apoptotic regulators have been reported to involve in regulation of apoptosis in activated macrophages, the causative relationship has yet to be established. In this report, we found that BAD phosphorylation, indicative of its inactivation, was increased in synovial sublining macrophages in arthritic mice and patients with RA. Using both loss-of-function and gain-of-function genetic approaches, we show that <italic>Bad</italic> loss augments the development of CIA by promoting survival and accumulation of synovial sublining macrophages, while constitutive activation of BAD prevents CIA progression by inducing apoptosis of synovial sublining macrophages. Thus, BAD is a key determinant for the development of experimental arthritis by regulating the survival of synovial sublining macrophages.</p><p>Our finding identifies BAD as a crucial player in experimental arthritis pathogenesis. Previous studies have shown that regulation of the maturation, activation, and function of different infiltrating immune cells in synovium can suppress or promote experimental arthritis pathogenesis in mice. For instance, genetic disruption of β-arrestin1 (<xref ref-type="bibr" rid="bib28">Li et al., 2013</xref>), IFT20 (<xref ref-type="bibr" rid="bib69">Yuan et al., 2014</xref>), and CD80/86 (<xref ref-type="bibr" rid="bib37">O'Neill et al., 2007</xref>) suppresses arthritis development by impairing T cell differentiation and activation, while loss of NFAT5 (<xref ref-type="bibr" rid="bib6">Choi et al., 2017</xref>), IKKβ (<xref ref-type="bibr" rid="bib2">Armaka et al., 2018</xref>), CIKS (<xref ref-type="bibr" rid="bib38">Pisitkun et al., 2010</xref>), and SIRT1 (<xref ref-type="bibr" rid="bib63">Woo et al., 2016</xref>) inhibits arthritis pathogenesis by promoting apoptosis in macrophages and fibroblasts, or inhibiting antibody production and dendritic cell maturation, respectively. On the other hand, genetic ablation of A20 (<xref ref-type="bibr" rid="bib33">Matmati et al., 2011</xref>), PGRN (<xref ref-type="bibr" rid="bib56">Tang et al., 2011</xref>), and CTRP6 (<xref ref-type="bibr" rid="bib36">Murayama et al., 2015</xref>) increased the susceptibility of mice to experimental arthritis development by promoting NF-κB activation, TNFα-mediated inflammation and complement activation, respectively. Our results show that arthritis pathogenesis was exacerbated in <italic>Bad</italic><sup>−/−</sup> mice in both CIA and TNF-Tg murine models of RA, but protected in <italic>Bad<sup>3SA/3SA</sup></italic> mice in CIA model, due to reduced or augmented apoptosis in synovial sublining macrophages, thereby adding BAD to the list of the key players that determine the susceptibility of mice to experimental arthritis.</p><p>BAD differentially regulates the survival of various infiltrating immune cells in experimental arthritis. Previous studies have shown that infiltrating innate immune cells like macrophages and adaptive immune cells such as CD4<sup>+</sup> T cells and B cells in sublining synovium contributes to arthritis pathogenesis, as elimination of macrophages, CD4<sup>+</sup> T cells, or B cells prevents arthritis development (<xref ref-type="bibr" rid="bib49">Solomon et al., 2005</xref>; <xref ref-type="bibr" rid="bib51">Svensson et al., 1998</xref>; <xref ref-type="bibr" rid="bib55">Taneja et al., 2002</xref>). Our results show that <italic>Bad</italic> loss led to accumulation of synovial sublining macrophages and B cells but not CD4<sup>+</sup> T cells, accompanying with reduced apoptosis in synovial sublining macrophages in CIA model. Consistently, <italic>Bad</italic> loss reduced apoptosis of synovial sublining macrophages in TNF-Tg mice, which is resulted from macrophage-mediated spontaneous inflammation with limited contribution of B cells and CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib47">Schinnerling et al., 2019</xref>). These results indicate that synovial sublining macrophages were more dependent on inactivation of BAD to resist apoptosis than other immune cells in the arthritic joints. This is likely due to, at least in part, distinct expression levels of BAD in different types of infiltrating immune cells, as BAD expression level is high in monocytes, which are the major source of synovial sublining macrophages (<xref ref-type="bibr" rid="bib58">Udalova et al., 2016</xref>), in bone marrow and peripheral blood but it is very low in spleen B cells and T cells and most tissue or organ fibroblasts (<xref ref-type="bibr" rid="bib25">Kitada et al., 1998</xref>). Further studies using the mice with conditionally deleted or mutated <italic>Bad</italic> in macrophages are needed to unambiguously ascribe the role of BAD in macrophages, given the possibility that <italic>Bad</italic> loss might affect the radio sensitivity of hematopoietic cells during the transplantation. By contrast, <italic>Bad</italic> loss appears to affect accumulation of B cells extrinsically, as bone marrow transplantation of <italic>Bad</italic>-deficient B cells failed to affect CIA progression in μMT mice. It is possible that B cell accumulation is the result of increased survival of synovial sublining macrophages, which are known to stimulate B cell proliferation (<xref ref-type="bibr" rid="bib7">Craxton et al., 2003</xref>). Although <italic>Bad</italic> loss did not affect CD4<sup>+</sup> T cell numbers in CIA model, expression of IL-21 that is mainly secreted by CD4<sup>+</sup> cells was significantly increased. Since IL-21 is known to promote B cell differentiation and proliferation (<xref ref-type="bibr" rid="bib13">Dienz et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Liu and King, 2013</xref>; <xref ref-type="bibr" rid="bib70">Zotos et al., 2010</xref>), CD4<sup>+</sup> T cells may also contribute to B cell accumulation in <italic>Bad</italic>-deficient CIA mouse model. Future studies are needed to determine the mechanism by which <italic>Bad</italic> loss affects CD4<sup>+</sup> T cell functions. Detailed mechanism apart, inactivation of BAD reduces apoptosis of synovial sublining macrophages intrinsically but increases accumulation of B cells extrinsically in CIA.</p><p>BAD is inactivated by Akt and IKK in synovial sublining macrophages in CIA. Previous studies have shown that the pro-apoptotic activity of BAD is inactivated by a group of protein kinases including Rsk2, PKA, Akt/PKB, and JNK1, which phosphorylate BAD at Ser112, Ser136, Ser155, or Thr201 (<xref ref-type="bibr" rid="bib9">Danial, 2008</xref>; <xref ref-type="bibr" rid="bib68">Yu et al., 2004</xref>), and IKK (<xref ref-type="bibr" rid="bib65">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="bib66">Yan et al., 2018</xref>), which phosphorylates BAD at Ser26 and primes its phosphorylation by other protein kinases, in response to survival factors/growth factors such as IL-3 and EGF or pro-inflammatory cytokine TNFα, respectively. Our results show that BAD in synovial sublining macrophages was inactivated by Akt and IKK in CIA model. Phosphorylation and activation of Akt and IKK were significantly increased in synovial sublining macrophages in the arthritic joints, in which increased levels of growth factors such as VEGF and PDGF are known to involve in inflammation, angiogenesis, and fibrosis (<xref ref-type="bibr" rid="bib57">Tas et al., 2016</xref>), while TNFα is known to mediate inflammation, angiogenesis, and osteoclasts formation and activation (<xref ref-type="bibr" rid="bib34">McInnes et al., 2016</xref>). Akt-mediated BAD Ser136-phosphorylation was also significantly increased in synovial sublining macrophages in CIA and TNF-Tg mice. Thus, BAD is the convergent node for Akt and IKK signaling pathways to confer the resistance to apoptosis on synovial sublining macrophages, thereby contributing to the pathogenesis of arthritis.</p><p>Our finding has important pathological significance and clinic relevance. The current RA therapies are mainly centered on anti-inflammation strategy aiming at reducing the detrimental effects of pro-inflammatory cytokines such as TNFα, IL-1, and IL-6 in RA, along with the utilization of immune-suppressors and small chemical JAK inhibitors (<xref ref-type="bibr" rid="bib15">Firestein and McInnes, 2017</xref>). However, the therapeutic efficacy varies among the patients with RA and the risk of overly infection due to immune suppression increases significantly over the time. Our results show that inactivation of BAD protects synovial sublining macrophages from apoptosis, thereby contributing to experimental arthritis pathology in both CIA and TNF-Tg murine models, and more importantly BAD inactivation by phosphorylation was significantly increased in synovial sublining macrophages in human specimens. Thus, reinvigoration of BAD pro-apoptotic activity in synovial sublining macrophages could provide a potential specific therapeutic strategy for RA therapy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Biological sample <break/>(<italic>Homo sapiens</italic>)</td><td>Synovial tissue of RA <break/>and OA patients</td><td>The University of Chicago</td><td>Department of Pathology’s <break/>diagnostic archive</td><td>Paraffin-embedded slides</td></tr><tr><td>Strain, strain background <break/><italic>Mus musculus</italic></td><td>CD45.1 mice <break/>(C57BL/6 congenic)</td><td>The Jackson Laboratory</td><td>Stock #:002014 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:002014">IMSR_JAX:002014</ext-link></td><td>B6.SJL-<italic>Ptprc<sup>a</sup> Pepc<sup>b</sup></italic>/BoyJ</td></tr><tr><td>Strain, strain background <break/><italic>Mus musculus</italic></td><td>μMT mice <break/>(C57BL/6 congenic)</td><td>The Jackson Laboratory</td><td>Stock #:002288 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:002288">IMSR_JAX:002288</ext-link></td><td>B6.129S2-<italic>Ighm<sup>tm1Cgn</sup></italic>/J</td></tr><tr><td>Antibody</td><td>Anti-BAD <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9292 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331419">AB_331419</ext-link></td><td>Immunoblotting (1:500)</td></tr><tr><td>Antibody</td><td>Anti-pBAD(S136) <break/>(rabbit monoclonal)</td><td>Cell Signaling Technology</td><td>Cat #:4366 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10547878">AB_10547878</ext-link></td><td>Immunoblotting (1:500) <break/>Immunofluorescence (1:100) <break/>Immunohistochemistry (1:100)</td></tr><tr><td>Antibody</td><td>Anti-pBAD(S112) <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9291 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331417">AB_331417</ext-link></td><td>Immunoblotting (1:500)</td></tr><tr><td>Antibody</td><td>Anti-pBAD(S155) <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9297 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2062131">AB_2062131</ext-link></td><td>Immunoblotting (1:500)</td></tr><tr><td>Antibody</td><td>Anti-pAkt(S473) <break/>(rabbit monoclonal)</td><td>Cell Signaling Technology</td><td>Cat #:4060 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2315049">AB_2315049</ext-link></td><td>Immunoblotting (1:1000) <break/>Immunofluorescence (1:100)</td></tr><tr><td>Antibody</td><td>Anti-Akt <break/>(rabbit monoclonal)</td><td>Cell Signaling Technology</td><td>Cat #:4691 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_915783">AB_915783</ext-link></td><td>Immunoblotting (1:1000)</td></tr><tr><td>Antibody</td><td>Anti-pIKKα/β <break/>(rabbit monoclonal)</td><td>Cell Signaling Technology</td><td>Cat #:2078 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2079379">AB_2079379</ext-link></td><td>Immunoblotting (1:500) <break/>Immunofluorescence (1:100)</td></tr><tr><td>Antibody</td><td>Anti-IKKβ <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:2684 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2122298">AB_2122298</ext-link></td><td>Immunoblotting (1:500)</td></tr><tr><td>Antibody</td><td>Anti-cleaved <break/>Caspase-3 <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9661 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2341188">AB_2341188</ext-link></td><td>Immunoblotting (1:500) <break/>Immunofluorescence (1:100)</td></tr><tr><td>Antibody</td><td>Anti-Caspase-3 <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9662 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331439">AB_331439</ext-link></td><td>Immunoblotting (1:500)</td></tr><tr><td>Antibody</td><td>Alexa Fluor <break/>488-conjugated <break/>cleaved Caspase-3 <break/>(rabbit polyclonal)</td><td>Cell Signaling Technology</td><td>Cat #:9669 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2069869">AB_2069869</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>Anti-Vimentin <break/>(chicken polyclonal)</td><td>Novus Biologicals</td><td>Cat #:NB300-223 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10003206">AB_10003206</ext-link></td><td>Immunofluorescence (1:100)</td></tr><tr><td>Antibody</td><td>Anti-BAD <break/>(rabbit monoclonal)</td><td>Abcam</td><td>Cat #:ab32445 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_725614">AB_725614</ext-link></td><td>Immunofluorescence (1:100)</td></tr><tr><td>Antibody</td><td>Anti-CD11b <break/>(rabbit monoclonal)</td><td>Abcam</td><td>Cat #:ab133357 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2650514">AB_2650514</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-F4/80 <break/>(rat monoclonal)</td><td>Abcam</td><td>Cat #:ab6640 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1140040">AB_1140040</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-CD45R <break/>(rat monoclonal)</td><td>Abcam</td><td>Cat #:ab64100 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1140036">AB_1140036</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-CD3 <break/>(rat monoclonal)</td><td>Abcam</td><td>Cat #:ab11089 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_369097">AB_369097</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-Vimentin <break/>(mouse monoclonal)</td><td>Abcam</td><td>Cat #:ab8069 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_306239">AB_306239</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-CD68 <break/>(mouse monoclonal)</td><td>Dako</td><td>Cat #:M0876 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2074844">AB_2074844</ext-link></td><td>Immunofluorescence (1:200)</td></tr><tr><td>Antibody</td><td>Anti-β-actin <break/>(mouse monoclonal)</td><td>Santa Cruz</td><td>Cat #:sc-47778 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2714189">AB_2714189</ext-link></td><td>Immunoblotting (1:2000)</td></tr><tr><td>Antibody</td><td>APC-conjugated <break/>anti-mouse CD11b <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:101211 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312794">AB_312794</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>BV421-conjugated <break/>anti-mouse F4/80 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:123131 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10901171">AB_10901171</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>APC-conjugated <break/>anti-mouse CD4 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:100411 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312696">AB_312696</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>BV421-conjugated <break/>anti-mouse CD4 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:100437 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10900241">AB_10900241</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>APC-conjugated <break/>anti-mouse/human <break/>CD45R/B220 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:103211 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312996">AB_312996</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>BV421-conjugated <break/>anti-mouse B220 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:103239 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10933424">AB_10933424</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>BV421-conjugated <break/>anti-mouse CD45 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:103133 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10899570">AB_10899570</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>FITC-conjugated <break/>anti-mouse CD45 <break/>(rat monoclonal)</td><td>Biolegend</td><td>Cat #:103107 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312972">AB_312972</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>APC-conjugated <break/>anti-mouse CD45.1 <break/>(mouse monoclonal)</td><td>Biolegend</td><td>Cat #:110713 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_313502">AB_313502</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>APCCy7-conjugated <break/>anti-mouse CD45.2 <break/>(mouse monoclonal)</td><td>Biolegend</td><td>Cat #:109824 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_830789">AB_830789</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>Alexa Fluor 594-conjugated <break/>anti-mouse Vimentin <break/>(mouse monoclonal)</td><td>Biolegend</td><td>Cat #:677804 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2566179">AB_2566179</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>PE-conjugated <break/>anti-mouse Gr1 <break/>(rat monoclonal)</td><td>eBioscience</td><td>Cat #:12-5931-82 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_466045">AB_466045</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Antibody</td><td>APC-conjugated <break/>anti-mouse Mac1 <break/>(rat monoclonal)</td><td>eBioscience</td><td>Cat #:17-0112-82 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_469343">AB_469343</ext-link></td><td>Flow cytometry (1:100)</td></tr><tr><td>Commercial <break/>assay or kit</td><td>FITC Annexin V Apoptosis <break/>Detection Kit I</td><td>BD Pharmingen</td><td>Cat #:556547</td><td>Flow cytometry (5 μl)</td></tr><tr><td>Commercial <break/>assay or kit</td><td>In Situ Cell Death <break/>Detection Kit</td><td>Roche</td><td>Cat #:11684817910</td><td>TUNEL staining</td></tr><tr><td>Commercial <break/>assay or kit</td><td>Mouse IL-1β ELISA Kit</td><td>R and D Systems</td><td>Cat #:MLB00C</td><td>ELISA</td></tr><tr><td>Commercial <break/>assay or kit</td><td>Mouse IL-6 ELISA Kit</td><td>R and D Systems</td><td>Cat #:M6000B</td><td>ELISA</td></tr><tr><td>Commercial <break/>assay or kit</td><td>Mouse TNFα ELISA Kit</td><td>R and D Systems</td><td>Cat #:MTA00B</td><td>ELISA</td></tr><tr><td>Commercial <break/>assay or kit</td><td>Mouse anti-dsDNA <break/>IgG ELISA Kit</td><td>Alpha Diagnostic</td><td>Cat #:5120</td><td>ELISA</td></tr><tr><td>Commercial <break/>assay or kit</td><td>Leukocyte Acid <break/>Phosphatase Kit</td><td>Sigma-Aldrich</td><td>Cat #:387A</td><td>TRAP staining</td></tr><tr><td>Software, algorithm</td><td>GraphPad Prism 6.0</td><td>GraphPad Prism</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">http://www.graphpad.com/</ext-link></td></tr><tr><td>Software, algorithm</td><td>ImageJ</td><td>ImageJ</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="https://imagej.net/">https://imagej.net/</ext-link></td></tr><tr><td>Software, algorithm</td><td>FlowJo 10</td><td>FlowJo</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008520">SCR_008520</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td></tr><tr><td>Software, algorithm</td><td>CytExpert</td><td>CytExpert Software</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_017217">SCR_017217</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="https://www.beckman.fr/flow-cytometry/instruments/cytoflex/software">https://www.beckman.fr/flow-cytometry/instruments/cytoflex/software</ext-link></td></tr><tr><td>Other</td><td>Chicken type II collagen</td><td>Chondrex</td><td>Cat #:20012</td><td>2 mg/ml</td></tr><tr><td>Other</td><td>Complete Freund’s <break/>adjuvant (CFA)</td><td>Chondrex</td><td>Cat #:7023</td><td>5 mg/ml heat-denatured <break/>mycobacterium</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Patient samples</title><p>Paraffin-embedded slides of synovial tissue from RA patients and OA patients (five each) were obtained from the Department of Pathology’s diagnostic archive of the University of Chicago with diagnostic reports with patients’ consent. The mean age of RA patients was 56 years old, ranging from 33 to 67 years old (female/male = 1.5). The mean age of OA patients was 65.4 years old, ranging from 55 to 75 (female/male = 1.5). This study was reviewed and approved by an Institutional Review Board (IRB) at the University of Chicago.</p></sec><sec id="s4-2"><title>Mice</title><p><italic>Bad</italic><sup>−/−</sup> and <italic>Bad<sup>3SA/3SA</sup></italic> mice have been previously described (<xref ref-type="bibr" rid="bib12">Datta et al., 2002</xref>; <xref ref-type="bibr" rid="bib41">Ranger et al., 2003</xref>). Briefly, <italic>Bad</italic><sup>−/−</sup> and <italic>Bad<sup>3SA/3SA</sup></italic> mice have been backcrossed into the C57BL/6J genetic background for at least 14 generations and validated by genome scanning to be 99.9% congenic with C57BL/6J. Heterozygous mice were further bred to generate knockout/knockin experimental mice and WT littermates. CD45.1 (B6.SJL-<italic>Ptprc<sup>a</sup> Pepc<sup>b</sup></italic>/BoyJ, #002014) mice and μMT (B6.129S2-<italic>Ighm<sup>tm1Cgn</sup></italic>/J, #002288) mice were purchased from the Jackson Laboratory. The 3647 line of TNF-Tg mice was generated by Dr. George Kollias (Institute of Immunology, Alexander Fleming Biomedical Sciences Research Center, Vari, Greece) (<xref ref-type="bibr" rid="bib22">Keffer et al., 1991</xref>). The TNF-Tg mice were bred as heterozygotes on a C57BL/6J background. TNF-Tg/<italic>Bad<sup>−/−</sup></italic> mice were generated by crossbreeding <italic>Bad</italic><sup>−/−</sup> mice with TNF-Tg mice. Only male mice were used and were randomly chosen for each genotype with age-matched. For clinical score of the mice and microscopic analysis of immunofluorescence staining, the experimenters were blinded to each genotype. All of the mice were maintained under specific pathogen-free conditions. Animal studies were approved by the Institutional Animal Care and Use Committee of Shanghai Institute of Biochemistry and Cell Biology or the Institutional Animal Care and Use Committee of the University of Chicago.</p></sec><sec id="s4-3"><title>Collagen-induced arthritis</title><p>CIA in C57BL/6 background mice was established, as previously reported (<xref ref-type="bibr" rid="bib20">Inglis et al., 2008</xref>). Briefly, 2 mg/ml chicken type II collagen (20012, Chondrex) was emulsified with an equal volume of complete Freund’s adjuvant (CFA) containing 5 mg/ml heat-denatured mycobacterium (7023, Chondrex). Eight to twelve weeks old mice were immunized intradermally at several sites near the base of the tail with 100 μl emulsion. A booster injection was administered on day 21 with the same emulsion of collagen II and CFA. The mice were monitored every other day after booster immunization. Development of arthritis was evaluated as described previously (<xref ref-type="bibr" rid="bib5">Campbell et al., 2000</xref>).</p></sec><sec id="s4-4"><title>Bone marrow transplantation</title><p>For bone marrow transplantation in CD45.1 mice, 6-week-old male recipient mice (CD45.1 background) were injected with one million bone marrow cells from donor mice of <italic>Bad</italic><sup>−/−</sup> or WT littermates (CD45.2 background) in 100 μl PBS within 24 hr after lethal irradiation of the recipient mice with two doses of 540 rad (total 1080 rad) delivered at least 2 hr apart by RS 2000 X-ray irradiator. The recipient mice were administrated Uniprim diet 1 week prior to irradiation and continuously treated with Uniprim diet for 2 weeks after transplantation to against infection. Six weeks later, the recipient mice were immunized with collagen II and CFA to establish the CIA model.</p><p>For bone marrow transplantation in μMT mice, the bone marrow cells from <italic>Bad</italic><sup>−/−</sup> and WT littermates were mixed with bone marrow cells from μMT mice as the ratio of 1:4 and then injected into lethally irradiated μMT mice (6-week-old) with 5 × 10<sup>6</sup> cells in 100 μl PBS per recipient within 24 hr after lethal irradiation. Six weeks later, the mice were immunized with collagen II and CFA to establish the CIA model.</p></sec><sec id="s4-5"><title>Radiography</title><p>Control and immunized WT and <italic>Bad</italic><sup>−/−</sup> mice were euthanized with CO<sub>2 </sub>63 days after the primary immunization and the hind paws were removed and fixed in 70% ethanol and analyzed by X-ray (Faxitron X-ray MX-20 Specimen Radiography System) and Micro-CT (Skyscan1172, Bruker Biospin) instrument.</p></sec><sec id="s4-6"><title>Histopathology</title><p>Hind limbs of the control mice or mice with CIA were removed, fixed in 4% PFA for 48 hr, decalcified in 15% EDTA (pH 7.8), and embedded in paraffin. Serial sections of ankle joints at 5 μm were cut and stained with H &amp; E and Safranin O. The evaluation of synovitis, pannus formation, as well as bone and cartilage destruction were determined by a graded scale as described previously (<xref ref-type="bibr" rid="bib56">Tang et al., 2011</xref>).</p></sec><sec id="s4-7"><title>Antibodies</title><p>Antibodies against BAD (#9292), pBAD(S136) (#4366), pBAD(S112) (#9291), pBAD(S155) (#9297), pAkt(S473) (#4060), Akt (#4691), pIKKα/β (#2078), IKKβ (#2684), cleaved Caspase-3 (#9661), Caspase-3 (#9662), and Alexa Fluor 488-conjugated cleaved Caspase-3 (#9669) were from Cell signaling Technologies (CST). Antibody against mouse Vimentin (NB300-223) was from Novus Biologicals. Antibodies against BAD (ab32445), CD11b (ab133357), F4/80 (ab6640), CD45R (ab64100), CD3 (ab11089), and human Vimentin (ab8069) were from Abcam. Antibodies against CD68 (M0876) and CD20 (IS604) were from Dako. Antibody against β-actin (sc-47778) was from Santa Cruz. APC-conjugated anti-mouse CD11b (M1/70) (101211), BV421-conjugated anti-mouse F4/80 (BM8) (123131), FITC-conjugated anti-mouse F4/80 (BM8) (11-4801-81), APC-conjugated anti-mouse CD4 (GK1.5) (100411), Alexa Fluor 594-conjugated anti-mouse Vimentin (O91D3) (677804), APC-conjugated anti-mouse B220 (RA3-6B2) (50-0452-82), APC-conjugated anti-mouse/human CD45R/B220 (RA3-6B2) (103211), BV421-conjugated anti-mouse B220 (RA3-6B2) (103239), PE-conjugated anti-mouse B220 (RA3-6B2) (12-0452-83), FITC-conjugated anti-mouse CD4 (GK1.5) (11-0041-85), BV421-conjugated anti-mouse CD4 (GK1.5) (100437), BV421-conjugated anti-mouse CD45 (30-F11) (103133), FITC-conjugated anti-mouse CD45 (30-F11) (103107), APC-conjugated anti-mouse CD45.1 (A20) (110713), FITC-conjugated anti-mouse CD45.2 (104) (109805), APCCy7-conjugated anti-mouse CD45.2 (109824), PE-conjugated anti-mouse Gr1 (12-5931-82), and APC-conjugated anti-mouse Mac1 (M1/70) (17-0112-82) were from Biolegend or eBioscience. Annexin V (556419) and APC-conjugated anti-mouse CD8 (53–6.7) (553035) were from BD Pharmingen.</p></sec><sec id="s4-8"><title>Immunofluorescence staining</title><p>Paraffin embedded slides of tissue were dewaxed in three containers of fresh xylene for 5 min each, and then rehydrated in 100% ethanol twice for 10 min each, 95% ethanol twice for 10 min each, and dH<sub>2</sub>O twice for 5 min each. Antigen retrieval was performed in pH 6.0 citrate buffer in water bath at 95°C for 10 min and cooled slides on bench top for 30 min, and then rinsed in dH<sub>2</sub>O for three times. Slides were then blocked in TBST (0.1% Tween-20) with 5% normal goat serum for 1 hr at room temperature and then incubated with primary antibody diluted in blocking buffer overnight at 4°C. Before staining with anti-pBAD(S136), primary antibody solution was incubated twice with membranes from SDS-PAGE loaded with <italic>Bad</italic><sup>−/−</sup> mouse joint extracts overnight to eliminate nonspecific bindings and immunoblotting analysis was performed to confirm the elimination of nonspecific bindings. Next day, slides were washed with TBST three times for 5 min each and incubated with corresponding Alexa-Fluor 488 and Alexa-Fluor 594 labeled secondary antibodies (Invitrogen) diluted in blocking buffer for 2 hr at room temperature in dark. The slides were washed with TBST three times for 5 min each, incubated with DAPI (Sigma) and washed with TBST three times for 5 min each. Slides were mounted with fluorescent mounting medium (Dako) and visualized by Olympus BX51 or Nikon Eclipse Ti2 microscope. Validation of antibodies used for immunofluorescence staining was showed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-9"><title>Immunohistochemistry staining</title><p>Paraffin embedded slides of mice or patients were dewaxed in xylene three times for 5 min each, and then rehydrated in 100% ethanol twice for 10 min each, 95% ethanol twice for 10 min each, and dH<sub>2</sub>O twice for 5 min each. Antigen retrieval was performed in pH 6.0 citrate buffer in water bath at 95°C for 10 min and cooled slides on bench top for 30 min and then rinsed slides in dH<sub>2</sub>O for three times. Incubated slides with 3% hydrogen peroxide for 10 min and rinsed slides in dH<sub>2</sub>O for two times. Slides were blocked in TBST with 5% normal goat serum for 1 hr at room temperature and then incubated with primary antibody diluted in blocking buffer overnight at 4°C. Slides were washed with TBST three times for 5 min each and incubated with one to three drops of SignalStain Boost Detection Reagent (#8114, CST) in a humidified chamber for 1 hr at room temperature. Slides were then washed with TBST three times for 5 min each and applied with 200 μl diluted SignalStain DAB (#8059, CST) for each section according to manufacturer instructions. Slides were immersed in dH<sub>2</sub>O and counterstained with Hematoxylin (#14166, CST) for 1 min. Sections were washed in dH<sub>2</sub>O twice for 5 min each and dehydrated in 95% ethanol twice for 10 s each, 100% ethanol twice for 10 s each, and xylene twice for 10 s each. Sections were then mounted with coverslips using mounting medium and visualized by Olympus BX51 or Nikon Eclipse Ti2 microscope.</p></sec><sec id="s4-10"><title>TUNEL assay</title><p>Apoptosis in paraffin embedded slides of synovium from CIA mice was detected using In Situ Cell Death Detection Kit (Cat No.11684817910, Roche) according to manufacturer’s instructions. In brief, paraffin embedded slides were dewaxed in xylene three times for 5 min each, and then rehydrated in 100% ethanol twice for 10 min each, 95% ethanol twice for 10 min each, and dH<sub>2</sub>O twice for 5 min each. Antigen retrieval was performed in 20 μg/ml Protein K solution for 20 min at 37°C and rinsed slides in PBS for five times. Then sections were incubated with TUNEL reaction mixture (prepared freshly before use) at 37°C for 1 hr in humidified chamber. Slides were incubated with DAPI (Sigma) and washed with PBS three times for 5 min each and mounted with fluorescent mounting medium (Dako) and visualized by Olympus BX51 or Nikon Eclipse Ti2 microscope.</p></sec><sec id="s4-11"><title>Immunoblotting</title><p>Total proteins of snap frozen joints were extracted in RIPA buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% deoxycholic acid sodium salt, 0.1% SDS, 1% NP-40, 1 mM EDTA, and 1 mM EGTA) with phosphatase and protease inhibitors (1 mM DTT, 1 mM PMSF, 1 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 μg/ml pepstatin). Samples were rotated at 4°C for 30 min. The protein concentration was measured by BCA assay. Equal amounts of proteins were subjected to SDS-PAGE gels. Proteins were transferred to PVDF membranes (Millipore). Membranes were blocked in 5% (w/v) skim milk or 3% bovine serum albumin (BSA) diluted in TBST for 1 hr at room temperature and then incubated with diluted primary antibody overnight at 4°C. Next day, membranes were washed with TBST three times for 10 min each and then incubated with HRP-linked anti-rabbit IgG (#7074, CST) or HRP-linked anti-mouse IgG (#7076, CST) secondary antibody for 1 hr at room temperature. Membranes were washed with TBST three times for 10 min each and then exposed by enhanced chemiluminescence method. Original blots for immunoblotting analysis were showed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-12"><title>Real-time quantitative PCR</title><p>Total RNA of snap frozen joints or cultured cells was extracted with TRIZOL reagent (No. 15596–018, Invitrogen), according to the manufacturer’s instructions. Reverse transcription of RNA to complementary DNA was performed using M-MLV Reverse Transcriptase (M1705, Promega). Real-time quantitative PCR (qPCR) was performed using SYBR Premix Ex Taq (#RR420A, TaKaRa) and the program for qPCR was 95°C for 30 s, 40 cycles of 95°C for 10 s, 55°C for 30 s, and 72°C for 30 s. The following primers were used for mRNA expression detection: TNFα (forward: <named-content content-type="sequence">CCAAGGCGCCACATCTCCCT</named-content>; reverse: <named-content content-type="sequence">GCTTTCTGTGCTCATGGTGT</named-content>), IL-6 (forward: <named-content content-type="sequence">TAGTCCTTCCTACCCCAATTTCC</named-content>; reverse: <named-content content-type="sequence">TTGGTCCTTAGCCACTCCTTC</named-content>), IL-1β (forward: <named-content content-type="sequence">GAAGAAGAGCCCATCCTCTG</named-content>; reverse: <named-content content-type="sequence">TCATCTCGGAGCCTGTAGTG</named-content>), IL-17A (forward: <named-content content-type="sequence">TTTAACTCCCTTGGCGCAAAA</named-content>; reverse: <named-content content-type="sequence">CTTTCCCTCCGCATTGACAC</named-content>), IL-4 (forward: <named-content content-type="sequence">GGTCTCAACCCCCAGCTAGT</named-content>; reverse: <named-content content-type="sequence">GCCGATGATCTCTCTCAAGTGAT</named-content>), IFN-γ (forward: <named-content content-type="sequence">ATGAACGCTACACACTGCATC</named-content>; reverse: <named-content content-type="sequence">CCATCCTTTTGCCAGTTCCTC</named-content>), IL-21 (forward: <named-content content-type="sequence">GGACCCTTGTCTGTCTGGTAG</named-content>; reverse: <named-content content-type="sequence">TGTGGAGCTGATAGAAGTTCAGG</named-content>), IL-10 (forward: <named-content content-type="sequence">GCTGGACAACATACTGCTAACC</named-content>, reverse: <named-content content-type="sequence">ATTTCCGATAAGGCTTGGCAA</named-content>), MMP-3 (forward: <named-content content-type="sequence">ACATGGAGACTTTGTCCCTTTTG</named-content>, reverse: <named-content content-type="sequence">TTGGCTGAGTGGTAGAGTCCC</named-content>), MMP-13 (forward: <named-content content-type="sequence">CTTCTTCTTGTTGAGCTGGACTC</named-content>, reverse: <named-content content-type="sequence">CTGTGGAGGTCACTGTAGACT</named-content>), TRAP (forward: <named-content content-type="sequence">CACTCCCACCCTGAGATTTGT</named-content>, reverse: <named-content content-type="sequence">CATCGTCTGCACGGTTCTG</named-content>), Cstk (forward: <named-content content-type="sequence">GAAGAAGACTCACCAGAAGCAG</named-content>, reverse: <named-content content-type="sequence">TCCAGGTTATGGGCAGAGATT</named-content>), and β-actin (forward: <named-content content-type="sequence">GGCTGTATTCCCCTCCATCG</named-content>, reverse: <named-content content-type="sequence">CCAGTTGGTAACAATGCCATGT</named-content>). Relative mRNA expression levels were calculated using the 2<sup>-∆∆Ct</sup> method.</p></sec><sec id="s4-13"><title>ELISA</title><p>For titration of collagen II-specific antibodies in CIA, 96-well plate (#9018, Corning) was coated with 100 μl of 5 μg/ml collagen II overnight at 4°C, followed by blocking with PBS containing 1% (w/v) BSA for 1 hr at room temperature. Diluted serum (begin at 1:100) was applied and incubated at room temperature for 2 hr. HRP-conjugated goat anti-mouse IgG (1030–05), IgG1 (1070–05), IgG2b (1090–05), IgG2c (1708–05), and IgG3 (1100–05), all of which were from SouthernBiotech, were added and incubated at room temperature for 2 hr, followed by incubation with 50 μl/well TMB (P0209, Beyotime) for 20 min in dark at room temperature and stopped by 25 μl/well 1M H<sub>2</sub>SO<sub>4</sub>. Color development was monitored at 450/540 nm by a microplates reader.</p><p>For detection of cytokines in the serum of mice with CIA, ELISA kits for mouse IL-1β (MLB00C, R and D Systems), mouse IL-6 (M6000B, R and D Systems), and mouse TNFα (MTA00B, R and D Systems) were used, according to the manufacturer’s instructions.</p><p>For detection of anti-dsDNA autoantibody in the serum of mice under normal condition, the Mouse anti-dsDNA IgG ELISA kit (5120, Alpha Diagnostic) was used, according to the manufacturer’s instructions.</p></sec><sec id="s4-14"><title>Flow cytometry</title><p>For flow cytometry of infiltrated cells in the joints of mice with CIA, the hind paws were harvested. After the skins were removed, the paws were minced and digested in collagenase II (2 mg/ml; Sigma C6885) and DNase I (0.1 mg/ml; Roche, 776785) in 5 ml HBSS at 37°C for 2 hr with vortex every 30 min. The digested cells were washed and passed through 70 μm cell strainers (BD Biosciences). Cells were counted and stained with cell surface markers or Annexin V, or fixed, permeabilized, and stained with intracellular cell marker or cleaved Caspase-3, and finally analyzed using LSR II (BD Biosciences) or CytoFLEX (Beckman) flow cytometer.</p><p>For flow cytometry of cells from spleen and lymph nodes (LNs) of mice with CIA, the spleen and LNs were isolated and washed in PBS containing 1% (w/v) BSA and minced into single-cell suspension. Cells isolated from spleen were subjected to red blood cell lysis. Isolated cells were counted and incubated with fluorochrome-conjugated antibodies for 30 min on ice. Stained cells were analyzed using LSR II flow cytometer.</p><p>For flow cytometry of cells from peripheral blood, about 10 μl peripheral blood was taken from the mouse tail vein and mixed with 100 μl 10 mM EDTA, and centrifuged at 300 ×<italic> g</italic> for 5 min at 4°C. Supernatant was removed and added 1 ml ACK buffer to remove red blood cells. Cells were then centrifuged again and resuspended with 100 μl staining buffer (0.1% BSA in PBS) to do staining.</p><p>For flow cytometry of BMDMs, about 8-week-old mice were euthanized by CO<sub>2</sub> and BMDMs were isolated from femur and tibia bones of mice and cultured in L929 conditioned completed DMEM medium supplemented with 10% (v/v) FBS and 1% penicillin/streptomycin (100 U/ml) at 37°C with 5% CO<sub>2</sub> for 7 days after removing red blood cells. After treatment, cells were collected by TE without EDTA, counted, and washed with PBS, then centrifuged at 300 ×<italic> g</italic> for 5 min at 4°C and resuspended with 100 μl Annexin V staining buffer. Cells were added 5 μl Annexin V for each tube and incubated at room temperature for 15 min in dark. Then cells were added 400 μl Annexin V staining buffer and analyzed using LSR-Fortessa 4–15 HTS flow cytometer (BD Biosciences).</p></sec><sec id="s4-15"><title>In vitro osteoclastogenesis</title><p>Bone marrow cells were harvested from femur and tibia bones. After removing red blood cells by adding ACK lysis buffer, cells were resuspended in DMEM medium containing 10% FBS, 20% L929 medium, and 1% penicillin/streptomycin, and then plated in 12-well plates. Medium was changed on day 3. After 7 days, bone marrow macrophages were cultured in the presence of 50 ng/ml M-CSF (416 ML, R and D systems) and 100 ng/ml RANKL (315–11, PeproTech) or 50 ng/ml M-CSF alone for another 7 days. The culture medium was changed every other day. Cells were then fixed and stained with TRAP (leukocyte acid phosphatase kit #387A; Sigma-Aldrich) and TRAP-positive multinucleated cells (TRAP<sup>+</sup> MNCs) were counted using light microscopy.</p></sec><sec id="s4-16"><title>TRAP staining</title><p>Paraffin embedded slides of joints were dewaxed in xylene and rehydrated in gradient ethanol and then incubated with the TRAP staining solution (leukocyte acid phosphatase kit #387A; Sigma-Aldrich), according to the manufacturer’s instructions. TRAP<sup>+</sup> MNCs were counted using light microscopy.</p></sec><sec id="s4-17"><title>Statistical analysis</title><p>Statistical analysis was performed using unpaired two-tailed Student’s <italic>t</italic>-test for comparison of two groups and using one-way ANOVA test for comparison of four groups. The severity of clinical score of CIA model was evaluated by Mann–Whitney <italic>U</italic>-test. For all statistical analysis, p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by National Institutes of Health grants (GM103868 to AL; CA195526 to JX; AI079087 and HL130724 to DW), and National Natural Science Foundation of China (31430026 and 91329301 to AL).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Funding acquisition</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Paraffin-embedded slides of synovial tissue from RA patients and OA patients were obtained from the Department of Pathology's diagnostic archive of the University of Chicago with diagnostic reports with patients' consent. This study was reviewed and approved by an Institutional Review Board (IRB) at the University of Chicago.</p></fn><fn fn-type="other"><p>Animal experimentation: Animal studies were approved by the Institutional Animal Care and Use Committee of Shanghai Institute of Biochemistry and Cell Biology (Permit Number: SIBCB-S332-1607-016) or the Institutional Animal Care and Use Committee of the University of Chicago (#71840).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Validation of antibodies used for immunofluorescence staining.</title><p>(A) Immunoblotting analysis of BAD. (B) Immunoblotting analysis of pBAD(S136) in joint extracts after removing nonspecific bands using <italic>Bad</italic><sup>−/−</sup> joint extracts. (C) Immunoblotting analysis of Vimentin. (D) Immunoblotting analysis of CD45R. (E) Immunoblotting analysis of F4/80. (F) Immunoblotting analysis of CD3. (G) Immunoblotting analysis of cleaved Casp-3 in mouse embryonic fibroblast (MEF) cells treated with TNFα (5 ng/ml) plus cycloheximide (CHX, 10 μg/ml). (H) Immunoblotting analysis of pBAD(S99) in THP-1 cells treated with TNFα (5 ng/ml). (I) Immunoblotting analysis of CD3 in THP-1 and Jurkat cell extracts. (J) Immunoblotting analysis of Vimentin in THP-1 and Hela cell extracts. (K) Immunoblotting analysis of CD68 in THP-1 and Jurkat cell extracts.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56309-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Original blots for immunoblotting analysis in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>, <xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig7">Figure 7A</xref>, and <xref ref-type="fig" rid="fig7">Figure 7G</xref>, as indicated.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56309-supp2-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-56309-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambarus</surname> <given-names>CA</given-names></name><name><surname>Noordenbos</surname> <given-names>T</given-names></name><name><surname>de Hair</surname> <given-names>MJ</given-names></name><name><surname>Tak</surname> <given-names>PP</given-names></name><name><surname>Baeten</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis</article-title><source>Arthritis Research &amp; Therapy</source><volume>14</volume><elocation-id>R74</elocation-id><pub-id pub-id-type="doi">10.1186/ar3796</pub-id><pub-id pub-id-type="pmid">22494514</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armaka</surname> <given-names>M</given-names></name><name><surname>Ospelt</surname> <given-names>C</given-names></name><name><surname>Pasparakis</surname> <given-names>M</given-names></name><name><surname>Kollias</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The p55TNFR-IKK2-Ripk3 Axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>618</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-02935-4</pub-id><pub-id pub-id-type="pmid">29434332</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrera</surname> <given-names>P</given-names></name><name><surname>Blom</surname> <given-names>A</given-names></name><name><surname>van Lent</surname> <given-names>PL</given-names></name><name><surname>van Bloois</surname> <given-names>L</given-names></name><name><surname>Beijnen</surname> <given-names>JH</given-names></name><name><surname>van Rooijen</surname> <given-names>N</given-names></name><name><surname>de Waal Malefijt</surname> <given-names>MC</given-names></name><name><surname>van de Putte</surname> <given-names>LB</given-names></name><name><surname>Storm</surname> <given-names>G</given-names></name><name><surname>van den Berg</surname> <given-names>WB</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis</article-title><source>Arthritis &amp; Rheumatism</source><volume>43</volume><fpage>1951</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200009)43:9&lt;1951::AID-ANR5&gt;3.0.CO;2-K</pub-id><pub-id pub-id-type="pmid">11014344</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresnihan</surname> <given-names>B</given-names></name><name><surname>Pontifex</surname> <given-names>E</given-names></name><name><surname>Thurlings</surname> <given-names>RM</given-names></name><name><surname>Vinkenoog</surname> <given-names>M</given-names></name><name><surname>El-Gabalawy</surname> <given-names>H</given-names></name><name><surname>Fearon</surname> <given-names>U</given-names></name><name><surname>Fitzgerald</surname> <given-names>O</given-names></name><name><surname>Gerlag</surname> <given-names>DM</given-names></name><name><surname>Rooney</surname> <given-names>T</given-names></name><name><surname>van de Sande</surname> <given-names>MG</given-names></name><name><surname>Veale</surname> <given-names>D</given-names></name><name><surname>Vos</surname> <given-names>K</given-names></name><name><surname>Tak</surname> <given-names>PP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers</article-title><source>The Journal of Rheumatology</source><volume>36</volume><fpage>1800</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.3899/jrheum.090348</pub-id><pub-id pub-id-type="pmid">19671815</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>IK</given-names></name><name><surname>Hamilton</surname> <given-names>JA</given-names></name><name><surname>Wicks</surname> <given-names>IP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis</article-title><source>European Journal of Immunology</source><volume>30</volume><fpage>1568</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200006)30:6&lt;1568::AID-IMMU1568&gt;3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">10898492</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>S</given-names></name><name><surname>You</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Choi</surname> <given-names>SY</given-names></name><name><surname>Kwon</surname> <given-names>HM</given-names></name><name><surname>Kim</surname> <given-names>HS</given-names></name><name><surname>Hwang</surname> <given-names>D</given-names></name><name><surname>Park</surname> <given-names>YJ</given-names></name><name><surname>Cho</surname> <given-names>CS</given-names></name><name><surname>Kim</surname> <given-names>WU</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>954</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1172/JCI87880</pub-id><pub-id pub-id-type="pmid">28192374</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craxton</surname> <given-names>A</given-names></name><name><surname>Magaletti</surname> <given-names>D</given-names></name><name><surname>Ryan</surname> <given-names>EJ</given-names></name><name><surname>Clark</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Macrophage- and dendritic cell--dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF</article-title><source>Blood</source><volume>101</volume><fpage>4464</fpage><lpage>4471</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-10-3123</pub-id><pub-id pub-id-type="pmid">12531790</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culemann</surname> <given-names>S</given-names></name><name><surname>Grüneboom</surname> <given-names>A</given-names></name><name><surname>Nicolás-Ávila</surname> <given-names>JÁ</given-names></name><name><surname>Weidner</surname> <given-names>D</given-names></name><name><surname>Lämmle</surname> <given-names>KF</given-names></name><name><surname>Rothe</surname> <given-names>T</given-names></name><name><surname>Quintana</surname> <given-names>JA</given-names></name><name><surname>Kirchner</surname> <given-names>P</given-names></name><name><surname>Krljanac</surname> <given-names>B</given-names></name><name><surname>Eberhardt</surname> <given-names>M</given-names></name><name><surname>Ferrazzi</surname> <given-names>F</given-names></name><name><surname>Kretzschmar</surname> <given-names>E</given-names></name><name><surname>Schicht</surname> <given-names>M</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Gelse</surname> <given-names>K</given-names></name><name><surname>Faas</surname> <given-names>M</given-names></name><name><surname>Pfeifle</surname> <given-names>R</given-names></name><name><surname>Ackermann</surname> <given-names>JA</given-names></name><name><surname>Pachowsky</surname> <given-names>M</given-names></name><name><surname>Renner</surname> <given-names>N</given-names></name><name><surname>Simon</surname> <given-names>D</given-names></name><name><surname>Haseloff</surname> <given-names>RF</given-names></name><name><surname>Ekici</surname> <given-names>AB</given-names></name><name><surname>Bäuerle</surname> <given-names>T</given-names></name><name><surname>Blasig</surname> <given-names>IE</given-names></name><name><surname>Vera</surname> <given-names>J</given-names></name><name><surname>Voehringer</surname> <given-names>D</given-names></name><name><surname>Kleyer</surname> <given-names>A</given-names></name><name><surname>Paulsen</surname> <given-names>F</given-names></name><name><surname>Schett</surname> <given-names>G</given-names></name><name><surname>Hidalgo</surname> <given-names>A</given-names></name><name><surname>Krönke</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Locally renewing resident synovial macrophages provide a protective barrier for the joint</article-title><source>Nature</source><volume>572</volume><fpage>670</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1471-1</pub-id><pub-id pub-id-type="pmid">31391580</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danial</surname> <given-names>NN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BAD: undertaker by night, candyman by day</article-title><source>Oncogene</source><volume>27 Suppl 1</volume><fpage>S53</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.44</pub-id><pub-id pub-id-type="pmid">19641507</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danial</surname> <given-names>NN</given-names></name><name><surname>Walensky</surname> <given-names>LD</given-names></name><name><surname>Zhang</surname> <given-names>CY</given-names></name><name><surname>Choi</surname> <given-names>CS</given-names></name><name><surname>Fisher</surname> <given-names>JK</given-names></name><name><surname>Molina</surname> <given-names>AJ</given-names></name><name><surname>Datta</surname> <given-names>SR</given-names></name><name><surname>Pitter</surname> <given-names>KL</given-names></name><name><surname>Bird</surname> <given-names>GH</given-names></name><name><surname>Wikstrom</surname> <given-names>JD</given-names></name><name><surname>Deeney</surname> <given-names>JT</given-names></name><name><surname>Robertson</surname> <given-names>K</given-names></name><name><surname>Morash</surname> <given-names>J</given-names></name><name><surname>Kulkarni</surname> <given-names>A</given-names></name><name><surname>Neschen</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name><name><surname>Corkey</surname> <given-names>BE</given-names></name><name><surname>Shirihai</surname> <given-names>OS</given-names></name><name><surname>Shulman</surname> <given-names>GI</given-names></name><name><surname>Lowell</surname> <given-names>BB</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dual role of proapoptotic BAD in insulin secretion and beta cell survival</article-title><source>Nature Medicine</source><volume>14</volume><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nm1717</pub-id><pub-id pub-id-type="pmid">18223655</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname> <given-names>SR</given-names></name><name><surname>Dudek</surname> <given-names>H</given-names></name><name><surname>Tao</surname> <given-names>X</given-names></name><name><surname>Masters</surname> <given-names>S</given-names></name><name><surname>Fu</surname> <given-names>H</given-names></name><name><surname>Gotoh</surname> <given-names>Y</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery</article-title><source>Cell</source><volume>91</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80405-5</pub-id><pub-id pub-id-type="pmid">9346240</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname> <given-names>SR</given-names></name><name><surname>Ranger</surname> <given-names>AM</given-names></name><name><surname>Lin</surname> <given-names>MZ</given-names></name><name><surname>Sturgill</surname> <given-names>JF</given-names></name><name><surname>Ma</surname> <given-names>YC</given-names></name><name><surname>Cowan</surname> <given-names>CW</given-names></name><name><surname>Dikkes</surname> <given-names>P</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis</article-title><source>Developmental Cell</source><volume>3</volume><fpage>631</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(02)00326-X</pub-id><pub-id pub-id-type="pmid">12431371</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dienz</surname> <given-names>O</given-names></name><name><surname>Eaton</surname> <given-names>SM</given-names></name><name><surname>Bond</surname> <given-names>JP</given-names></name><name><surname>Neveu</surname> <given-names>W</given-names></name><name><surname>Moquin</surname> <given-names>D</given-names></name><name><surname>Noubade</surname> <given-names>R</given-names></name><name><surname>Briso</surname> <given-names>EM</given-names></name><name><surname>Charland</surname> <given-names>C</given-names></name><name><surname>Leonard</surname> <given-names>WJ</given-names></name><name><surname>Ciliberto</surname> <given-names>G</given-names></name><name><surname>Teuscher</surname> <given-names>C</given-names></name><name><surname>Haynes</surname> <given-names>L</given-names></name><name><surname>Rincon</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells</article-title><source>Journal of Experimental Medicine</source><volume>206</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1084/jem.20081571</pub-id><pub-id pub-id-type="pmid">19139170</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Evolving concepts of rheumatoid arthritis</article-title><source>Nature</source><volume>423</volume><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/nature01661</pub-id><pub-id pub-id-type="pmid">12748655</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname> <given-names>GS</given-names></name><name><surname>McInnes</surname> <given-names>IB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunopathogenesis of rheumatoid arthritis</article-title><source>Immunity</source><volume>46</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.006</pub-id><pub-id pub-id-type="pmid">28228278</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname> <given-names>J</given-names></name><name><surname>Burnham</surname> <given-names>V</given-names></name><name><surname>Tedoldi</surname> <given-names>M</given-names></name><name><surname>Danial</surname> <given-names>NN</given-names></name><name><surname>Yellen</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BAD knockout provides metabolic seizure resistance in a genetic model of epilepsy with sudden unexplained death in epilepsy</article-title><source>Epilepsia</source><volume>59</volume><fpage>e1</fpage><lpage>e4</lpage><pub-id pub-id-type="doi">10.1111/epi.13960</pub-id><pub-id pub-id-type="pmid">29171006</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handel</surname> <given-names>ML</given-names></name><name><surname>McMorrow</surname> <given-names>LB</given-names></name><name><surname>Gravallese</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Nuclear factor-kappa B in rheumatoid synovium. localization of p50 and p65</article-title><source>Arthritis &amp; Rheumatism</source><volume>38</volume><fpage>1762</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1002/art.1780381209</pub-id><pub-id pub-id-type="pmid">8849348</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haringman</surname> <given-names>JJ</given-names></name><name><surname>Gerlag</surname> <given-names>DM</given-names></name><name><surname>Zwinderman</surname> <given-names>AH</given-names></name><name><surname>Smeets</surname> <given-names>TJ</given-names></name><name><surname>Kraan</surname> <given-names>MC</given-names></name><name><surname>Baeten</surname> <given-names>D</given-names></name><name><surname>McInnes</surname> <given-names>IB</given-names></name><name><surname>Bresnihan</surname> <given-names>B</given-names></name><name><surname>Tak</surname> <given-names>PP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</article-title><source>Annals of the Rheumatic Diseases</source><volume>64</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.029751</pub-id><pub-id pub-id-type="pmid">15576415</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>QQ</given-names></name><name><surname>Birkett</surname> <given-names>R</given-names></name><name><surname>Doyle</surname> <given-names>RE</given-names></name><name><surname>Haines</surname> <given-names>GK</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name><name><surname>Shi</surname> <given-names>B</given-names></name><name><surname>Homan</surname> <given-names>P</given-names></name><name><surname>Xing</surname> <given-names>L</given-names></name><name><surname>Pope</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association of increased F4/80<sup>high</sup>macrophages with suppression of Serum-Transfer arthritis in mice with reduced FLIP in myeloid cells</article-title><source>Arthritis &amp; Rheumatology</source><volume>69</volume><fpage>1762</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1002/art.40151</pub-id><pub-id pub-id-type="pmid">28511285</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inglis</surname> <given-names>JJ</given-names></name><name><surname>Simelyte</surname> <given-names>E</given-names></name><name><surname>McCann</surname> <given-names>FE</given-names></name><name><surname>Criado</surname> <given-names>G</given-names></name><name><surname>Williams</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Protocol for the induction of arthritis in C57BL/6 mice</article-title><source>Nature Protocols</source><volume>3</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.19</pub-id><pub-id pub-id-type="pmid">18388943</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname> <given-names>Y</given-names></name><name><surname>Ding</surname> <given-names>H</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Bcl-XL and Mcl-1 upregulation by calreticulin promotes apoptosis resistance of fibroblast-like synoviocytes via activation of PI3K/Akt and STAT3 pathways in rheumatoid arthritis</article-title><source>Clinical and Experimental Rheumatology</source><volume>36</volume><fpage>841</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">29652658</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keffer</surname> <given-names>J</given-names></name><name><surname>Probert</surname> <given-names>L</given-names></name><name><surname>Cazlaris</surname> <given-names>H</given-names></name><name><surname>Georgopoulos</surname> <given-names>S</given-names></name><name><surname>Kaslaris</surname> <given-names>E</given-names></name><name><surname>Kioussis</surname> <given-names>D</given-names></name><name><surname>Kollias</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis</article-title><source>The EMBO Journal</source><volume>10</volume><fpage>4025</fpage><lpage>4031</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb04978.x</pub-id><pub-id pub-id-type="pmid">1721867</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname> <given-names>TD</given-names></name><name><surname>Plater-Zyberk</surname> <given-names>C</given-names></name><name><surname>Partridge</surname> <given-names>TA</given-names></name><name><surname>Woodrow</surname> <given-names>DF</given-names></name><name><surname>Maini</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Morphometric comparison of synovium from patients with osteoarthritis and rheumatoid arthritis</article-title><source>Journal of Clinical Pathology</source><volume>41</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1136/jcp.41.8.847</pub-id><pub-id pub-id-type="pmid">3262630</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname> <given-names>A</given-names></name><name><surname>Fearon</surname> <given-names>U</given-names></name><name><surname>Veale</surname> <given-names>DJ</given-names></name><name><surname>Godson</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Macrophages in synovial inflammation</article-title><source>Frontiers in Immunology</source><volume>2</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2011.00052</pub-id><pub-id pub-id-type="pmid">22566842</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname> <given-names>S</given-names></name><name><surname>Krajewska</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Scudiero</surname> <given-names>D</given-names></name><name><surname>Zapata</surname> <given-names>JM</given-names></name><name><surname>Wang</surname> <given-names>HG</given-names></name><name><surname>Shabaik</surname> <given-names>A</given-names></name><name><surname>Tudor</surname> <given-names>G</given-names></name><name><surname>Krajewski</surname> <given-names>S</given-names></name><name><surname>Myers</surname> <given-names>TG</given-names></name><name><surname>Johnson</surname> <given-names>GS</given-names></name><name><surname>Sausville</surname> <given-names>EA</given-names></name><name><surname>Reed</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines</article-title><source>The American Journal of Pathology</source><volume>152</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9422523</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurowska-Stolarska</surname> <given-names>M</given-names></name><name><surname>Alivernini</surname> <given-names>S</given-names></name><name><surname>Ballantine</surname> <given-names>LE</given-names></name><name><surname>Asquith</surname> <given-names>DL</given-names></name><name><surname>Millar</surname> <given-names>NL</given-names></name><name><surname>Gilchrist</surname> <given-names>DS</given-names></name><name><surname>Reilly</surname> <given-names>J</given-names></name><name><surname>Ierna</surname> <given-names>M</given-names></name><name><surname>Fraser</surname> <given-names>AR</given-names></name><name><surname>Stolarski</surname> <given-names>B</given-names></name><name><surname>McSharry</surname> <given-names>C</given-names></name><name><surname>Hueber</surname> <given-names>AJ</given-names></name><name><surname>Baxter</surname> <given-names>D</given-names></name><name><surname>Hunter</surname> <given-names>J</given-names></name><name><surname>Gay</surname> <given-names>S</given-names></name><name><surname>Liew</surname> <given-names>FY</given-names></name><name><surname>McInnes</surname> <given-names>IB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis</article-title><source>PNAS</source><volume>108</volume><fpage>11193</fpage><lpage>11198</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019536108</pub-id><pub-id pub-id-type="pmid">21690378</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Hsu</surname> <given-names>HC</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Edgington</surname> <given-names>LE</given-names></name><name><surname>Bogyo</surname> <given-names>M</given-names></name><name><surname>Kimberly</surname> <given-names>RP</given-names></name><name><surname>Mountz</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model</article-title><source>Arthritis &amp; Rheumatism</source><volume>64</volume><fpage>1098</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1002/art.33423</pub-id><pub-id pub-id-type="pmid">22006294</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wei</surname> <given-names>B</given-names></name><name><surname>Guo</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Du</surname> <given-names>F</given-names></name><name><surname>Fan</surname> <given-names>W</given-names></name><name><surname>Bao</surname> <given-names>C</given-names></name><name><surname>Pei</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Deficiency of β-arrestin1 ameliorates collagen-induced arthritis with impaired TH17 cell differentiation</article-title><source>PNAS</source><volume>110</volume><fpage>7395</fpage><lpage>7400</lpage><pub-id pub-id-type="doi">10.1073/pnas.1221608110</pub-id><pub-id pub-id-type="pmid">23589893</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Schwarz</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The TNF-alpha transgenic mouse model of inflammatory arthritis</article-title><source>Springer Seminars in Immunopathology</source><volume>25</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00281-003-0125-3</pub-id><pub-id pub-id-type="pmid">12904889</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name><name><surname>Pagliari</surname> <given-names>LJ</given-names></name><name><surname>Pope</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. role of Mcl-1, independent of nuclear factor (NF)-kappaB, bad, or caspase activation</article-title><source>The Journal of Experimental Medicine</source><volume>194</volume><fpage>113</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1084/jem.194.2.113</pub-id><pub-id pub-id-type="pmid">11457886</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Huang</surname> <given-names>Q</given-names></name><name><surname>Shi</surname> <given-names>B</given-names></name><name><surname>Eksarko</surname> <given-names>P</given-names></name><name><surname>Temkin</surname> <given-names>V</given-names></name><name><surname>Pope</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages</article-title><source>Arthritis &amp; Rheumatism</source><volume>54</volume><fpage>3174</fpage><lpage>3181</lpage><pub-id pub-id-type="doi">10.1002/art.22132</pub-id><pub-id pub-id-type="pmid">17009247</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>SM</given-names></name><name><surname>King</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IL-21-producing th cells in immunity and autoimmunity</article-title><source>The Journal of Immunology</source><volume>191</volume><fpage>3501</fpage><lpage>3506</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301454</pub-id><pub-id pub-id-type="pmid">24058193</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matmati</surname> <given-names>M</given-names></name><name><surname>Jacques</surname> <given-names>P</given-names></name><name><surname>Maelfait</surname> <given-names>J</given-names></name><name><surname>Verheugen</surname> <given-names>E</given-names></name><name><surname>Kool</surname> <given-names>M</given-names></name><name><surname>Sze</surname> <given-names>M</given-names></name><name><surname>Geboes</surname> <given-names>L</given-names></name><name><surname>Louagie</surname> <given-names>E</given-names></name><name><surname>Mc Guire</surname> <given-names>C</given-names></name><name><surname>Vereecke</surname> <given-names>L</given-names></name><name><surname>Chu</surname> <given-names>Y</given-names></name><name><surname>Boon</surname> <given-names>L</given-names></name><name><surname>Staelens</surname> <given-names>S</given-names></name><name><surname>Matthys</surname> <given-names>P</given-names></name><name><surname>Lambrecht</surname> <given-names>BN</given-names></name><name><surname>Schmidt-Supprian</surname> <given-names>M</given-names></name><name><surname>Pasparakis</surname> <given-names>M</given-names></name><name><surname>Elewaut</surname> <given-names>D</given-names></name><name><surname>Beyaert</surname> <given-names>R</given-names></name><name><surname>van Loo</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis</article-title><source>Nature Genetics</source><volume>43</volume><fpage>908</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1038/ng.874</pub-id><pub-id pub-id-type="pmid">21841782</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname> <given-names>IB</given-names></name><name><surname>Buckley</surname> <given-names>CD</given-names></name><name><surname>Isaacs</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cytokines in rheumatoid arthritis - shaping the immunological landscape</article-title><source>Nature Reviews Rheumatology</source><volume>12</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2015.171</pub-id><pub-id pub-id-type="pmid">26656659</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname> <given-names>IB</given-names></name><name><surname>Schett</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The pathogenesis of rheumatoid arthritis</article-title><source>New England Journal of Medicine</source><volume>365</volume><fpage>2205</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1004965</pub-id><pub-id pub-id-type="pmid">22150039</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murayama</surname> <given-names>MA</given-names></name><name><surname>Kakuta</surname> <given-names>S</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Umeda</surname> <given-names>N</given-names></name><name><surname>Yonezawa</surname> <given-names>T</given-names></name><name><surname>Maruhashi</surname> <given-names>T</given-names></name><name><surname>Tateishi</surname> <given-names>K</given-names></name><name><surname>Ishigame</surname> <given-names>H</given-names></name><name><surname>Yabe</surname> <given-names>R</given-names></name><name><surname>Ikeda</surname> <given-names>S</given-names></name><name><surname>Seno</surname> <given-names>A</given-names></name><name><surname>Chi</surname> <given-names>HH</given-names></name><name><surname>Hashiguchi</surname> <given-names>Y</given-names></name><name><surname>Kurata</surname> <given-names>R</given-names></name><name><surname>Tada</surname> <given-names>T</given-names></name><name><surname>Kubo</surname> <given-names>S</given-names></name><name><surname>Sato</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Hattori</surname> <given-names>M</given-names></name><name><surname>Saijo</surname> <given-names>S</given-names></name><name><surname>Matsushita</surname> <given-names>M</given-names></name><name><surname>Fujita</surname> <given-names>T</given-names></name><name><surname>Sumida</surname> <given-names>T</given-names></name><name><surname>Iwakura</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8483</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9483</pub-id><pub-id pub-id-type="pmid">26404464</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname> <given-names>SK</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Hamel</surname> <given-names>KM</given-names></name><name><surname>Doodes</surname> <given-names>PD</given-names></name><name><surname>Hutas</surname> <given-names>G</given-names></name><name><surname>Finnegan</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis</article-title><source>The Journal of Immunology</source><volume>179</volume><fpage>5109</fpage><lpage>5116</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.8.5109</pub-id><pub-id pub-id-type="pmid">17911596</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisitkun</surname> <given-names>P</given-names></name><name><surname>Claudio</surname> <given-names>E</given-names></name><name><surname>Ren</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Siebenlist</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody</article-title><source>Arthritis &amp; Rheumatism</source><volume>62</volume><fpage>3334</fpage><lpage>3344</lpage><pub-id pub-id-type="doi">10.1002/art.27653</pub-id><pub-id pub-id-type="pmid">20662069</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Apoptosis as a therapeutic tool in rheumatoid arthritis</article-title><source>Nature Reviews Immunology</source><volume>2</volume><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/nri846</pub-id><pub-id pub-id-type="pmid">12094227</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekhar</surname> <given-names>M</given-names></name><name><surname>Olsson</surname> <given-names>AM</given-names></name><name><surname>Steel</surname> <given-names>KJ</given-names></name><name><surname>Georgouli</surname> <given-names>M</given-names></name><name><surname>Ranasinghe</surname> <given-names>U</given-names></name><name><surname>Brender Read</surname> <given-names>C</given-names></name><name><surname>Frederiksen</surname> <given-names>KS</given-names></name><name><surname>Taams</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis</article-title><source>Journal of Autoimmunity</source><volume>79</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2017.01.002</pub-id><pub-id pub-id-type="pmid">28118944</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranger</surname> <given-names>AM</given-names></name><name><surname>Zha</surname> <given-names>J</given-names></name><name><surname>Harada</surname> <given-names>H</given-names></name><name><surname>Datta</surname> <given-names>SR</given-names></name><name><surname>Danial</surname> <given-names>NN</given-names></name><name><surname>Gilmore</surname> <given-names>AP</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Le Beau</surname> <given-names>MM</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Bad-deficient mice develop diffuse large B cell lymphoma</article-title><source>PNAS</source><volume>100</volume><fpage>9324</fpage><lpage>9329</lpage><pub-id pub-id-type="doi">10.1073/pnas.1533446100</pub-id><pub-id pub-id-type="pmid">12876200</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname> <given-names>PJ</given-names></name><name><surname>Williams</surname> <given-names>AS</given-names></name><name><surname>Goodfellow</surname> <given-names>RM</given-names></name><name><surname>Williams</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis</article-title><source>Rheumatology</source><volume>38</volume><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/38.9.818</pub-id><pub-id pub-id-type="pmid">10515641</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname> <given-names>KS</given-names></name><name><surname>Al-Muftah</surname> <given-names>MA</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Al-Kowari</surname> <given-names>MK</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Ismail Chouchane</surname> <given-names>A</given-names></name><name><surname>Kizhakayil</surname> <given-names>D</given-names></name><name><surname>Kulik</surname> <given-names>G</given-names></name><name><surname>Marincola</surname> <given-names>FM</given-names></name><name><surname>Haoudi</surname> <given-names>A</given-names></name><name><surname>Chouchane</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting proapoptotic protein BAD inhibits survival and self-renewal of Cancer stem cells</article-title><source>Cell Death &amp; Differentiation</source><volume>21</volume><fpage>1936</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.140</pub-id><pub-id pub-id-type="pmid">25215949</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scatizzi</surname> <given-names>JC</given-names></name><name><surname>Bickel</surname> <given-names>E</given-names></name><name><surname>Hutcheson</surname> <given-names>J</given-names></name><name><surname>Haines</surname> <given-names>GK</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis</article-title><source>Arthritis &amp; Rheumatism</source><volume>54</volume><fpage>3182</fpage><lpage>3193</lpage><pub-id pub-id-type="doi">10.1002/art.22133</pub-id><pub-id pub-id-type="pmid">17009248</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scatizzi</surname> <given-names>JC</given-names></name><name><surname>Hutcheson</surname> <given-names>J</given-names></name><name><surname>Bickel</surname> <given-names>E</given-names></name><name><surname>Haines</surname> <given-names>GK</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pro-apoptotic bid is required for the resolution of the effector phase of inflammatory arthritis</article-title><source>Arthritis Research &amp; Therapy</source><volume>9</volume><elocation-id>R49</elocation-id><pub-id pub-id-type="doi">10.1186/ar2204</pub-id><pub-id pub-id-type="pmid">17509138</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scatizzi</surname> <given-names>JC</given-names></name><name><surname>Hutcheson</surname> <given-names>J</given-names></name><name><surname>Pope</surname> <given-names>RM</given-names></name><name><surname>Firestein</surname> <given-names>GS</given-names></name><name><surname>Koch</surname> <given-names>AE</given-names></name><name><surname>Mavers</surname> <given-names>M</given-names></name><name><surname>Smason</surname> <given-names>A</given-names></name><name><surname>Agrawal</surname> <given-names>H</given-names></name><name><surname>Haines</surname> <given-names>GK</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name><name><surname>Hotchkiss</surname> <given-names>RS</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis</article-title><source>Arthritis &amp; Rheumatism</source><volume>62</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1002/art.27198</pub-id><pub-id pub-id-type="pmid">20112357</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schinnerling</surname> <given-names>K</given-names></name><name><surname>Rosas</surname> <given-names>C</given-names></name><name><surname>Soto</surname> <given-names>L</given-names></name><name><surname>Thomas</surname> <given-names>R</given-names></name><name><surname>Aguillón</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Humanized mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of Cell-Based therapies</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>203</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00203</pub-id><pub-id pub-id-type="pmid">30837986</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siouti</surname> <given-names>E</given-names></name><name><surname>Andreakos</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The many facets of macrophages in rheumatoid arthritis</article-title><source>Biochemical Pharmacology</source><volume>165</volume><fpage>152</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2019.03.029</pub-id><pub-id pub-id-type="pmid">30910693</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname> <given-names>S</given-names></name><name><surname>Rajasekaran</surname> <given-names>N</given-names></name><name><surname>Jeisy-Walder</surname> <given-names>E</given-names></name><name><surname>Snapper</surname> <given-names>SB</given-names></name><name><surname>Illges</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis</article-title><source>European Journal of Immunology</source><volume>35</volume><fpage>3064</fpage><lpage>3073</lpage><pub-id pub-id-type="doi">10.1002/eji.200526167</pub-id><pub-id pub-id-type="pmid">16180250</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname> <given-names>D</given-names></name><name><surname>Na</surname> <given-names>YR</given-names></name><name><surname>Hwang</surname> <given-names>ES</given-names></name><name><surname>Seok</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through akt and bad phosphorylation</article-title><source>Journal of Biological Chemistry</source><volume>289</volume><fpage>6225</fpage><lpage>6235</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.508994</pub-id><pub-id pub-id-type="pmid">24421315</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname> <given-names>L</given-names></name><name><surname>Jirholt</surname> <given-names>J</given-names></name><name><surname>Holmdahl</surname> <given-names>R</given-names></name><name><surname>Jansson</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>B cell-deficient mice do not develop type II collagen-induced arthritis (CIA)</article-title><source>Clinical &amp; Experimental Immunology</source><volume>111</volume><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00529.x</pub-id><pub-id pub-id-type="pmid">9528892</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szekanecz</surname> <given-names>Z</given-names></name><name><surname>Koch</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Macrophages and their products in rheumatoid arthritis</article-title><source>Current Opinion in Rheumatology</source><volume>19</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1097/BOR.0b013e32805e87ae</pub-id><pub-id pub-id-type="pmid">17414958</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname> <given-names>PP</given-names></name><name><surname>Smeets</surname> <given-names>TJ</given-names></name><name><surname>Daha</surname> <given-names>MR</given-names></name><name><surname>Kluin</surname> <given-names>PM</given-names></name><name><surname>Meijers</surname> <given-names>KA</given-names></name><name><surname>Brand</surname> <given-names>R</given-names></name><name><surname>Meinders</surname> <given-names>AE</given-names></name><name><surname>Breedveld</surname> <given-names>FC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</article-title><source>Arthritis &amp; Rheumatism</source><volume>40</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1002/art.1780400206</pub-id><pub-id pub-id-type="pmid">9041933</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname> <given-names>PP</given-names></name><name><surname>Bresnihan</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis</article-title><source>Arthritis &amp; Rheumatism</source><volume>43</volume><fpage>2619</fpage><lpage>2633</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200012)43:12&lt;2619::AID-ANR1&gt;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">11145019</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname> <given-names>V</given-names></name><name><surname>Taneja</surname> <given-names>N</given-names></name><name><surname>Paisansinsup</surname> <given-names>T</given-names></name><name><surname>Behrens</surname> <given-names>M</given-names></name><name><surname>Griffiths</surname> <given-names>M</given-names></name><name><surname>Luthra</surname> <given-names>H</given-names></name><name><surname>David</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis</article-title><source>The Journal of Immunology</source><volume>168</volume><fpage>5867</fpage><lpage>5875</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.11.5867</pub-id><pub-id pub-id-type="pmid">12023391</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Tian</surname> <given-names>QY</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>FJ</given-names></name><name><surname>Liu</surname> <given-names>GY</given-names></name><name><surname>Syed</surname> <given-names>NM</given-names></name><name><surname>Lai</surname> <given-names>Y</given-names></name><name><surname>Lin</surname> <given-names>EA</given-names></name><name><surname>Kong</surname> <given-names>L</given-names></name><name><surname>Su</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>F</given-names></name><name><surname>Ding</surname> <given-names>AH</given-names></name><name><surname>Zanin-Zhorov</surname> <given-names>A</given-names></name><name><surname>Dustin</surname> <given-names>ML</given-names></name><name><surname>Tao</surname> <given-names>J</given-names></name><name><surname>Craft</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>Z</given-names></name><name><surname>Feng</surname> <given-names>JQ</given-names></name><name><surname>Abramson</surname> <given-names>SB</given-names></name><name><surname>Yu</surname> <given-names>XP</given-names></name><name><surname>Liu</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice</article-title><source>Science</source><volume>332</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1126/science.1199214</pub-id><pub-id pub-id-type="pmid">21393509</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tas</surname> <given-names>SW</given-names></name><name><surname>Maracle</surname> <given-names>CX</given-names></name><name><surname>Balogh</surname> <given-names>E</given-names></name><name><surname>Szekanecz</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeting of proangiogenic signalling pathways in chronic inflammation</article-title><source>Nature Reviews Rheumatology</source><volume>12</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2015.164</pub-id><pub-id pub-id-type="pmid">26633288</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udalova</surname> <given-names>IA</given-names></name><name><surname>Mantovani</surname> <given-names>A</given-names></name><name><surname>Feldmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Macrophage heterogeneity in the context of rheumatoid arthritis</article-title><source>Nature Reviews Rheumatology</source><volume>12</volume><fpage>472</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2016.91</pub-id><pub-id pub-id-type="pmid">27383913</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uderhardt</surname> <given-names>S</given-names></name><name><surname>Martins</surname> <given-names>AJ</given-names></name><name><surname>Tsang</surname> <given-names>JS</given-names></name><name><surname>Lämmermann</surname> <given-names>T</given-names></name><name><surname>Germain</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resident macrophages cloak tissue microlesions to prevent Neutrophil-Driven inflammatory damage</article-title><source>Cell</source><volume>177</volume><fpage>541</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.02.028</pub-id><pub-id pub-id-type="pmid">30955887</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schouwenburg</surname> <given-names>PA</given-names></name><name><surname>Rispens</surname> <given-names>T</given-names></name><name><surname>Wolbink</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis</article-title><source>Nature Reviews Rheumatology</source><volume>9</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2013.4</pub-id><pub-id pub-id-type="pmid">23399692</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergadi</surname> <given-names>E</given-names></name><name><surname>Ieronymaki</surname> <given-names>E</given-names></name><name><surname>Lyroni</surname> <given-names>K</given-names></name><name><surname>Vaporidi</surname> <given-names>K</given-names></name><name><surname>Tsatsanis</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Akt signaling pathway in macrophage activation and M1/M2 polarization</article-title><source>The Journal of Immunology</source><volume>198</volume><fpage>1006</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601515</pub-id><pub-id pub-id-type="pmid">28115590</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>S</given-names></name><name><surname>Kitaura</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>P</given-names></name><name><surname>Ross</surname> <given-names>FP</given-names></name><name><surname>Teitelbaum</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>IL-1 mediates TNF-induced osteoclastogenesis</article-title><source>Journal of Clinical Investigation</source><volume>115</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1172/JCI200523394</pub-id><pub-id pub-id-type="pmid">15668736</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>SM</given-names></name><name><surname>Lim</surname> <given-names>HS</given-names></name><name><surname>Hah</surname> <given-names>YS</given-names></name><name><surname>Jung</surname> <given-names>ID</given-names></name><name><surname>Park</surname> <given-names>YM</given-names></name><name><surname>Kim</surname> <given-names>HO</given-names></name><name><surname>Cheon</surname> <given-names>YH</given-names></name><name><surname>Jeon</surname> <given-names>MG</given-names></name><name><surname>Jang</surname> <given-names>KY</given-names></name><name><surname>Kim</surname> <given-names>KM</given-names></name><name><surname>Park</surname> <given-names>BH</given-names></name><name><surname>Lee</surname> <given-names>SI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Myeloid deletion of SIRT1 suppresses collagen-induced arthritis in mice by modulating dendritic cell maturation</article-title><source>Experimental &amp; Molecular Medicine</source><volume>48</volume><elocation-id>e221</elocation-id><pub-id pub-id-type="doi">10.1038/emm.2015.124</pub-id><pub-id pub-id-type="pmid">26987484</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Guo</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Ni</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor necrosis factor alpha promotes osteoclast formation via PI3K/Akt Pathway-Mediated Blimp1 expression upregulation</article-title><source>Journal of Cellular Biochemistry</source><volume>118</volume><fpage>1308</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1002/jcb.25672</pub-id><pub-id pub-id-type="pmid">27505147</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Xiang</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Danial</surname> <given-names>NN</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inactivation of BAD by IKK inhibits TNFα-induced apoptosis independently of NF-κB activation</article-title><source>Cell</source><volume>152</volume><fpage>304</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.12.021</pub-id><pub-id pub-id-type="pmid">23332762</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Xiang</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Lin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The BH3-only protein BAD mediates TNFα cytotoxicity despite concurrent activation of IKK and NF-κB in septic shock</article-title><source>Cell Research</source><volume>28</volume><fpage>701</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/s41422-018-0041-7</pub-id><pub-id pub-id-type="pmid">29795446</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>E</given-names></name><name><surname>Zha</surname> <given-names>J</given-names></name><name><surname>Jockel</surname> <given-names>J</given-names></name><name><surname>Boise</surname> <given-names>LH</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces bax and promotes cell death</article-title><source>Cell</source><volume>80</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90411-5</pub-id><pub-id pub-id-type="pmid">7834748</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Minemoto</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>F</given-names></name><name><surname>Bui</surname> <given-names>TN</given-names></name><name><surname>Xiang</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD</article-title><source>Molecular Cell</source><volume>13</volume><fpage>329</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(04)00028-0</pub-id><pub-id pub-id-type="pmid">14967141</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Garrett-Sinha</surname> <given-names>LA</given-names></name><name><surname>Sarkar</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Deletion of IFT20 in early stage T lymphocyte differentiation inhibits the development of collagen-induced arthritis</article-title><source>Bone Research</source><volume>2</volume><elocation-id>14038</elocation-id><pub-id pub-id-type="doi">10.1038/boneres.2014.38</pub-id><pub-id pub-id-type="pmid">26097753</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zotos</surname> <given-names>D</given-names></name><name><surname>Coquet</surname> <given-names>JM</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Light</surname> <given-names>A</given-names></name><name><surname>D'Costa</surname> <given-names>K</given-names></name><name><surname>Kallies</surname> <given-names>A</given-names></name><name><surname>Corcoran</surname> <given-names>LM</given-names></name><name><surname>Godfrey</surname> <given-names>DI</given-names></name><name><surname>Toellner</surname> <given-names>KM</given-names></name><name><surname>Smyth</surname> <given-names>MJ</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name><name><surname>Tarlinton</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism</article-title><source>Journal of Experimental Medicine</source><volume>207</volume><fpage>365</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1084/jem.20091777</pub-id><pub-id pub-id-type="pmid">20142430</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56309.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Reviewing Editor</role><aff><institution>Yale School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Tuckermann</surname><given-names>Jan P</given-names></name><role>Reviewer</role><aff><institution>University of Ulm</institution><country>Germany</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Pope</surname><given-names>Richard</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study elegantly combines genetic and immunological approaches to reveal the role of the pro-apoptotic protein BAD in the inflammatory response associated with rheumatoid arthritis. The authors provide a link between inflammation and the inactivation of BAD as a key pathological mechanism leading to the survival of macrophages in the synovium. This discovery could pave the way for new therapeutic interventions centered on the modulation of BAD function in this disease.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;BAD inactivation exacerbates rheumatoid arthritis pathology by promoting survival of sublining macrophages&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jan P Tuckermann (Reviewer #1); Richard Pope (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Summary:</p><p>This is a carefully conducted study on the functional role of BAD in the pathogenesis of experimental arthritis and in rheumatoid arthritis (RA). The study makes use of independent models of experimental arthritis (collagen-induced arthritis and to a lesser extent TNF-tg induced arthritis) together with knockout mice. Disabling BAD function is shown to reduce apoptosis of macrophages in the sublinear layer and thereby lead to exaggerated inflammatory responses and subsequent erosion. The study also reports increased BAD phosphorylation in synovial tissue macrophages in RA compared with OA, supporting the clinical relevance of their finding in murine models. Overall, this is an important contribution to the field. However, the conclusion that the phenotype described is solely due to the loss of BAD function in macrophages is not entirely supported by the data.</p><p>The following comments are made to clarify the results presented and conclusions drawn.</p><p>Essential revisions:</p><p>1) The use of mice with conditionally deleted or mutated <italic>Bad</italic> would further strengthened the importance of BAD in macrophages in experimental arthritis. If such data is available, it should be included. While we acknowledge that this would be a major effort if the mice are not available to the authors, the authors should in such a case discuss that further studies would be needed to unambiguously ascribe a function role of BAD in macrophages and refer to the role of BAD in radio sensitive hematopoietic cells.</p><p>2) The authors use 2-color IHC to a large extent to identify cell types that are positive for TUNNEL, activated caspase 3, and pBAD. The approach would be strengthened if some of these observations were confirmed by flow cytometry. Figure 3F does not seem totally consistent with Figure 3G or Figure 5D with Figure 5B.</p><p>3) A clarification of the cell types positive for cleaved caspase 3 is merited. For example, why in the entire ankle cleaved caspase 3 activity is reduced in BAD deficient animals, whereas on histology only macrophages seemed to be affected (which make up to 10% of the tissue cells?).</p><p>4) Important controls should be included. For example, the levels of pBAD in non-arthritic joints (e.g. in Figure 4D, E) should be shown. The basal expression of BAD in the distinct cell populations (FLS, B cells, T cells, Neutrophils) should be elaborated and compared to macrophages.</p><p>5) Please be consistent when referring to CIA as an experimental model of RA. In some places, experimental arthritis is incorrectly called RA.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56309.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The use of mice with conditionally deleted or mutated Bad would further strengthened the importance of BAD in macrophages in experimental arthritis. If such data is available, it should be included. While we acknowledge that this would be a major effort if the mice are not available to the authors, the authors should in such a case discuss that further studies would be needed to unambiguously ascribe a function role of BAD in macrophages and refer to the role of BAD in radio sensitive hematopoietic cells.</p></disp-quote><p>We totally agree with the reviewers that the usage of mice with conditionally deleted or mutated <italic>Bad</italic> would further strengthen the importance of BAD in macrophages in experimental arthritis, given the possibility that <italic>Bad</italic> loss may affect the radio sensitive hematopoietic cells. Unfortunately, these mouse strains are not available for us. In the previous manuscript, we used bone marrow transplantation model to demonstrate the important role of BAD in macrophages (Figure 3). In the revised manuscript, we further analyzed the sensitivity of isolated synovial macrophages, B cells, CD4<sup>+</sup> T cells and fibroblasts from WT and <italic>Bad<sup>-/-</sup></italic> mice in CIA model to apoptosis by flow cytometry (new Figure 2C, D, new Figure 2—figure supplement 5, new Figure 2—figure supplement 6, new Figure 2—figure supplement 7). The new data are consistent with our previous conclusion that <italic>Bad</italic>-deficient macrophages, but not B cells, CD4<sup>+</sup> T cells or fibroblasts, are resistant to apoptosis in vivo. In the revised Discussion, we have indicated that such conditional <italic>Bad</italic> knockout or mutant mice are needed to unambiguously ascribe the role of BAD in macrophages, given the possibility that <italic>Bad</italic> loss may affect the radio sensitive hematopoietic cells.</p><disp-quote content-type="editor-comment"><p>2) The authors use 2-color IHC to a large extent to identify cell types that are positive for TUNNEL, activated caspase 3, and pBAD. The approach would be strengthened if some of these observations were confirmed by flow cytometry. Figure 3F does not seem totally consistent with Figure 3G or Figure 5D with Figure 5B.</p></disp-quote><p>We thank the reviewers for these great suggestions. As suggested by the reviewers, in the revised manuscript we performed flow cytometry analysis with Alexa Fluor 488-conjugated cleaved caspase-3 antibody to compare the ratio of apoptotic cells among macrophages, B cells, CD4<sup>+</sup> T cells and synovial fibroblasts. The results show that the ratio of apoptotic synovial macrophages, but not other cell types examined, was significantly reduced both in <italic>Bad<sup>-/-</sup></italic> mice in CIA model and TNF-Tg/<italic>Bad<sup>-/-</sup></italic> mice (new Figure 2C, D, new Figure 2—figure supplement 6, and new Figure 6F, G), consistent with our previous data showing that macrophage is the major cell type significantly affected by <italic>Bad</italic> loss using TUNEL assay, activated caspase-3 and pBAD staining (Figure 2—figure supplement 4, Figure 2A, B and Figure 4D, E). The same results were obtained when Annexin V was used as another apoptotic indicator to label apoptotic cells isolated from the synovium (new Figure 2—figure supplement 5 and new Figure 2—figure supplement 7). These data further support our conclusion that <italic>Bad</italic> loss mainly affects the apoptosis of synovial macrophages in experimental arthritic murine models used. In addition, we replaced the pictures in Figure 3F and Figure 5B to make the figures to be consistent with the statistical analysis.</p><disp-quote content-type="editor-comment"><p>3) A clarification of the cell types positive for cleaved caspase 3 is merited. For example, why in the entire ankle cleaved caspase 3 activity is reduced in BAD deficient animals, whereas on histology only macrophages seemed to be affected (which make up to 10% of the tissue cells?).</p></disp-quote><p>We thank the reviewers for the excellent questions. The reviewer is correct that the cleaved caspase-3 activity is reduced in the joint extracts of <italic>Bad<sup>-/-</sup></italic> mice compared with WT mice in CIA model, indicating that <italic>Bad</italic> loss inhibits the apoptosis of the cells in experimental arthritis. To identify which cell type is mainly affected by <italic>Bad</italic> loss, we did TUNEL staining along with different cell markers and found that macrophages were mainly affected among different cell types in the joint (revised Figure 2—figure supplement 4). In addition, cleaved caspase-3 staining assay with macrophage marker further demonstrated that there was a difference in macrophage apoptosis between WT and <italic>Bad<sup>-/-</sup></italic> mice joints in CIA model (Figure 2A, B). Furthermore, cleaved caspase-3 flow cytometry assay demonstrated that <italic>Bad</italic> loss mainly affected macrophage apoptosis (new Figure 2C, D, new Figure 2—figure supplement 6). The reason why only macrophage apoptosis is mainly affected is most likely due to distinct expression levels of BAD in different types of infiltrating immune cells, as discussed in the revised manuscript Discussion. Thus, synovial sublining macrophages may be more dependent on inactivation of BAD to resist apoptosis than other immune cells in the arthritic joints. To avoid any confusion, in the revised manuscript we stated that <italic>Bad</italic> loss mainly affects macrophage apoptosis, while apoptosis of other cell types appear to be less affected.</p><disp-quote content-type="editor-comment"><p>4) Important controls should be included. For example, the levels of pBAD in non-arthritic joints (e.g. in Figure 4D, E) should be shown. The basal expression of BAD in the distinct cell populations (FLS, B cells, T cells, Neutrophils) should be elaborated and compared to macrophages.</p></disp-quote><p>We thank the reviewers for these great suggestions. Accordingly, we have included the controls of BAD staining in arthritic joints (new Figure 4—figure supplement 1) and pBAD staining in non-arthritic joints (new Figure 4—figure supplement 2) for Figure 4D, E. We also included the data of BAD staining in RA synovium (new Figure 8—figure supplement 1) as the control of Figure 8C, D in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) Please be consistent when referring to CIA as an experimental model of RA. In some places, experimental arthritis is incorrectly called RA.</p></disp-quote><p>We apology for the ignorance and have corrected this mistake.</p></body></sub-article></article>